RayKnowChina Research Map
Shortlist

GuangzhouSouthern Medical University

Nanfang Hospital

南方医科大学南方医院

Listed for 29 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Nanfang Hospital

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Nasopharyngeal carcinoma鼻咽癌33 papers led6 open trials led
  2. Oesophageal squamous cell carcinoma食管鳞状细胞癌8 papers led4 open trials led
  3. Hepatocellular carcinoma肝细胞癌127 papers led7 open trials led
  4. Stomach cancer胃癌127 papers led12 open trials led
  5. Hepatoblastoma肝母细胞瘤0 papers led
  6. Retinoblastoma视网膜母细胞瘤0 papers led
  7. Osteosarcoma骨肉瘤6 papers led
  8. Gastrointestinal stromal tumour胃肠道间质瘤2 papers led
  9. Neuroblastoma神经母细胞瘤2 papers led
  10. Multiple myeloma多发性骨髓瘤3 papers led
  11. B-cell acute lymphoblastic leukaemiaB 细胞急性淋巴细胞白血病8 papers led
  12. Beta thalassaemiaβ 地中海贫血21 papers led
  13. Haemophilia A血友病 A9 papers led
  14. Atypical haemolytic uraemic syndrome非典型溶血性尿毒症综合征1 paper led
  15. Neuromyelitis optica spectrum disorder视神经脊髓炎谱系疾病3 papers led
  16. Myasthenia gravis重症肌无力1 paper led
  17. Moyamoya disease烟雾病6 papers led
  18. Anti-NMDA receptor encephalitis抗 NMDA 受体脑炎7 papers led
  19. Idiopathic pulmonary fibrosis特发性肺纤维化5 papers led
  20. Amyotrophic lateral sclerosis肌萎缩侧索硬化症6 papers led
  21. Spinal muscular atrophy脊髓性肌萎缩症1 paper led
  22. Fabry disease法布雷病2 papers led
  23. Duchenne muscular dystrophy杜氏肌营养不良0 papers led
  24. Alport syndromeAlport 综合征0 papers led
  25. IgA nephropathyIgA 肾病5 papers led1 open trial led
  26. Primary biliary cholangitis原发性胆汁性胆管炎1 paper led
  27. Congenital diaphragmatic hernia先天性膈疝1 paper led
  28. Hirschsprung disease先天性巨结肠0 papers led
  29. Familial adenomatous polyposis家族性腺瘤性息肉病2 papers led

Not listed for: Chordoma, Ewing sarcoma, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Thrombotic thrombocytopenic purpura, Fanconi anaemia, IgG4-related disease, Wilson disease, Biliary atresia, Takayasu arteritis, Hepatic echinococcosis, Lymphangioleiomyomatosis, Pompe disease, Behçet disease, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary sclerosing cholangitis, Inherited epidermolysis bullosa, Hereditary angioedema, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Nasopharyngeal carcinoma

鼻咽癌

Led 33 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 1.4%.

Papers led
33
2021–2025
Trials led
8
any status, ClinicalTrials.gov
Open trials led
6
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 111120212022: 3320222023: 5520232024: 8820242025: 662025

23 hospitals in Guangzhou for nasopharyngeal carcinoma176 hospitals in China for nasopharyngeal carcinoma

Open trials with this hospital 8

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Dynamic Risk Prediction of Severe Myelosuppression in Nasopharyngeal Carcinoma
    Phase
    Not given
    Started
    2026-08
    Registry
    NCT07819656

    Age 18 years to Not stated (registered criteria)

    Led by Nanfang HospitalGuangzhou

  2. Recruiting
    A Mucosal Contouring Method Based on Swallowing-induced Breakthrough Pain for Radiation-induced Oropharyngeal Mucositis
    Phase
    Not given
    Started
    2024-03
    Registry
    NCT06287788

    Age 18 years to Not stated (registered criteria)

    Led by Nanfang HospitalGuangzhou

  3. Recruiting
    Plasma SAA1 Levels in Predicting Response to Radiotherapy-induced Oral Mucositis
    Phase
    Not given
    Started
    2024-02
    Registry
    NCT06307314

    Age 18 years to Not stated (registered criteria)

    Led by Nanfang HospitalGuangzhou

  4. Recruiting
    A Real-world Observational Study of a Mucosal Contouring Method for Radiation-induced Oropharyngeal Mucositis
    Phase
    Not given
    Started
    2024-04
    Registry
    NCT06308328

    Age 18 years to Not stated (registered criteria)

    Led by Nanfang Hospital; 9 listed hospitals as study sitesChengdu, Guangzhou, Shanghai, Shaoguan, Shenzhen, Zhuhai

  5. Recruiting
    Doxepin Solution for Alleviation of Stubborn Breakthrough Pain Induced by Swallowing in Patients Receiving Radiotherapy for Nasopharyngeal Carcinoma
    Phase
    N/A
    Started
    2023-10
    Registry
    NCT06017895

    Age 18 years to Not stated (registered criteria)

    Led by Nanfang HospitalGuangzhou

  6. Recruiting
    Cisplatin-based and Carboplatin-based Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma
    Phase
    Phase 3
    Started
    2018-01
    Registry
    NCT03919552

    Age 18 years to 64 years (registered criteria)

    Led by Nanfang HospitalGuangzhou

  7. Recruiting
    Adebrelimab and Chemoradiotherapy in High-risk LANPC
    Phase
    Phase 2
    Started
    2024-07
    Registry
    NCT06349889

    Age 18 years to 65 years (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 3 listed hospitals as study sitesChengdu, Guangzhou, Xiamen

  8. Recruiting
    Toripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal Carcinoma
    Phase
    Phase 3
    Started
    2021-03
    Registry
    NCT04778956

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesFoshan, Guangzhou, Zhongshan

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRecurrent / metastatic diseaseRadiotherapy techniqueImaging & AI
Departments in papersRadiation oncologyENT / head & neck surgery
Papers it led33
  1. The impact of different cervical planning target volume designs on efficacy and toxicity in nasopharyngeal carcinoma: a single-center retrospective study.2025BMC cancerFree full text
  2. Exosomal PD-L1 derived from hypoxia nasopharyngeal carcinoma cell exacerbates CD8+ T cell suppression by promoting PD-L1 upregulation in macrophages.2025Cancer immunology, immunotherapy : CIIFree full text
  3. METTL14 Regulates the Expression of Genes Related to Interferon, Interleukin and MHC Class I in Nasopharyngeal Carcinoma Cells.2025Cancer medicineFree full text
  4. Comparative Analysis of Hearing Loss Induced by Cisplatin Versus Carboplatin in Locally Advanced Nasopharyngeal Carcinoma: Early to Mid-Term Findings.2025Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery
  5. CircTBCD/IGF2BP2 complex stabilizes IGF-1R mRNA in an m6A-dependent manner to promote bone metastasis in nasopharyngeal carcinoma.2025International journal of biological macromolecules
  6. A dynamic online nomogram for predicting nutritional risk in nasopharyngeal carcinoma patients after radiotherapy.2025Supportive care in cancer : official journal of the Multinational Association of Supportive Care in CancerFree full text
  7. VLDL and LDL Subfractions Enhance the Risk Stratification of Individuals Who Underwent Epstein-Barr Virus-Based Screening for Nasopharyngeal Carcinoma: A Multicenter Cohort Study.2024Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  8. Construction and application of nasopharyngeal carcinoma-specific big data platform based on electronic health records.2024American journal of otolaryngology
  9. GSTM3 enhances radiosensitivity of nasopharyngeal carcinoma by promoting radiation-induced ferroptosis through USP14/FASN axis and GPX4.2024British journal of cancerFree full text
  10. Plasma Metabolic Profiles-Based Prediction of Induction Chemotherapy Efficacy in Nasopharyngeal Carcinoma: Results of a Bidirectional Clinical Trial.2024Clinical cancer research : an official journal of the American Association for Cancer ResearchFree full text
  11. A Preliminary Study on Transcriptional Regulation of SNP Site C-1888T in the Promoter Region of Human PLUNC Gene and Nasopharyngeal Carcinoma Susceptibility.2024Genetics researchFree full text
  12. A novel EIF3C-related CD8+ T-cell signature in predicting prognosis and immunotherapy response of nasopharyngeal carcinoma.2024Journal of cancer research and clinical oncologyFree full text
  13. ThermomiR-377-3p-induced suppression of Cirbp expression is required for effective elimination of cancer cells and cancer stem-like cells by hyperthermia.2024Journal of experimental & clinical cancer research : CRFree full text
  14. IGF-1R mediates crosstalk between nasopharyngeal carcinoma cells and osteoclasts and promotes tumor bone metastasis.2024Journal of experimental & clinical cancer research : CRFree full text
  15. Targeting Glutamine Metabolism through Glutaminase Inhibition Suppresses Cell Proliferation and Progression in Nasopharyngeal Carcinoma.2023Anti-cancer agents in medicinal chemistry
  16. Nomogram incorporating Epstein-Barr virus DNA and a novel immune-nutritional marker for survival prediction in nasopharyngeal carcinoma.2023BMC cancerFree full text
  17. Impact of sex on treatment-related adverse effects and prognosis in nasopharyngeal carcinoma.2023BMC cancerFree full text
  18. Assessment and management of radiation-induced trismus in patients with nasopharyngeal carcinoma: a best practice implementation project.2023JBI evidence implementation
  19. Systemic immune-inflammation index during treatment predicts prognosis and guides clinical treatment in patients with nasopharyngeal carcinoma.2023Journal of cancer research and clinical oncologyFree full text
  20. Combination of smoking and Epstein-Barr virus DNA is a predictor of poor prognosis for nasopharyngeal carcinoma: a long-term follow-up retrospective study.2022BMC cancerFree full text
  21. Prognostic value of systemic inflammation response index in nasopharyngeal carcinoma with negative Epstein-Barr virus DNA.2022BMC cancerFree full text
  22. CYLD deficiency enhances metabolic reprogramming and tumor progression in nasopharyngeal carcinoma via PFKFB3.2022Cancer letters
  23. Expression and Biological Functions of EPC1 in Nasopharyngeal Carcinoma.2021Archives of Iranian medicine
  24. Survival benefit of induction chemotherapy for locally advanced nasopharyngeal carcinoma: prognosis based on a new risk estimation model.2021BMC cancerFree full text
  25. Study on structured method of Chinese MRI report of nasopharyngeal carcinoma.2021BMC medical informatics and decision makingFree full text
  26. Long-term monitoring of dynamic changes in plasma EBV DNA for improved prognosis prediction of nasopharyngeal carcinoma.2021Cancer medicineFree full text
  27. Foxq1 promotes metastasis of nasopharyngeal carcinoma by inducing vasculogenic mimicry via the EGFR signaling pathway.2021Cell death & diseaseFree full text
  28. Intense Diffuse Uptake of 68Ga-FAPI-04 in the Breasts Found by PET/CT in a Patient With Advanced Nasopharyngeal Carcinoma.2021Clinical nuclear medicine
  29. Epstein-Barr virus (EBV) encoded microRNA BART8-3p drives radioresistance-associated metastasis in nasopharyngeal carcinoma.2021Journal of cellular physiology
  30. Cancer-associated fibroblasts promote the survival of irradiated nasopharyngeal carcinoma cells via the NF-κB pathway.2021Journal of experimental & clinical cancer research : CRFree full text
  31. Protein tyrosine phosphatase receptor type D gene promotes radiosensitivity via STAT3 dephosphorylation in nasopharyngeal carcinoma.2021OncogeneFree full text
  32. Diffusion weighted imaging in submandibular gland sparing helical tomotherapy for nasopharyngeal carcinoma.2021Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  33. Functional Study of Polymorphism 1888 C>T in the Promoter Region of Human PLUNC Gene.2021The American journal of the medical sciences
All its trials on ClinicalTrials.gov, any status15
  1. Dynamic Risk Prediction of Severe Myelosuppression in Nasopharyngeal CarcinomaRecruitingNCT07819656Lead sponsorStart 2026-08
  2. A Mucosal Contouring Method Based on Swallowing-induced Breakthrough Pain for Radiation-induced Oropharyngeal MucositisRecruitingNCT06287788Lead sponsorStart 2024-03
  3. A Real-world Observational Study of a Mucosal Contouring Method for Radiation-induced Oropharyngeal MucositisRecruitingNCT06308328Lead sponsorStart 2024-04
  4. Plasma SAA1 Levels in Predicting Response to Radiotherapy-induced Oral MucositisRecruitingNCT06307314Lead sponsorStart 2024-02
  5. Doxepin Solution for Alleviation of Stubborn Breakthrough Pain Induced by Swallowing in Patients Receiving Radiotherapy for Nasopharyngeal CarcinomaRecruitingNCT06017895Lead sponsorN/AStart 2023-10
  6. Cisplatin-based and Carboplatin-based Chemoradiation in Locoregionally Advanced Nasopharyngeal CarcinomaRecruitingNCT03919552Lead sponsorPhase 3Start 2018-01
  7. A Bidirectional Study in Exploring the Dynamic Changes of Plasma and Urine Metabolites of Nasopharyngeal Carcinoma.Status unknownNCT05682703Lead sponsorStart 2022-12
  8. Camrelizumab After Completion of Radiotherapy for Oligometastatic Nasopharyngeal CarcinomaStatus unknownNCT04221516Lead sponsorPhase 2Start 2020-01
  9. Adebrelimab and Chemoradiotherapy in High-risk LANPCRecruitingNCT06349889Study sitePhase 2Start 2024-07
  10. Toripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal CarcinomaRecruitingNCT04778956Study sitePhase 3Start 2021-03
  11. Detection and Biopsy Guidance of Nasopharyngeal Carcinoma Based on Artificial Intelligence and Endoscopic ImagesStatus unknownNCT05202626Study siteStart 2021-12
  12. A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal CarcinomaActive, not recruitingNCT04974398Study sitePhase 3Start 2021-08
  13. Effect of Oral Nutritional Supplements on Body Weight Loss of Patients With Nasopharyngeal CarcinomaCompletedNCT04823468Study siteN/AStart 2021-07
  14. The Efficacy and Safety Study of TORIPALIMAB INJECTION Combined With Chemotherapy for Nasophapyngeal CancerCompletedNCT03581786Study sitePhase 3Start 2018-10
  15. The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCCStatus unknownNCT02915432Study sitePhase 1/Phase 2Start 2016-12
More papers found outside PubMed (not counted)20
  1. A randomized, open-label, multicenter, blank-controlled, phase IV clinical trial of Biyan Qingdu Granula in attenuating acute nose and oral damage in patients undergoing radiotherapy for nasopharyngeal carcinoma.2025Journal of Clinical Oncologyconference-abstract
  2. Abstract CT011: Penpulimab versus placebo in combination with chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: A global, multicenter, randomized, double-blind, phase 3 trial (AK105-304)2025Cancer Researchconference-abstract
  3. Evaluation of PD-L1 expression status in nasopharyngeal carcinoma by 18F-FDG PET/CT radiomics analysis2025International Journal of Radiation Researcharticle
  4. A multi-gene predictive model for the radiation sensitivity of nasopharyngeal carcinoma based on machine learning2024eLifepreprint
  5. Author response: A multi-gene predictive model for the radiation sensitivity of nasopharyngeal carcinoma based on machine learning2024eLifepeer-review
  6. EGFR-Regulated EMT is a Driver of Vasculogenic Mimicry in Nasopharyngeal Carcinoma2023Journal on oncologyarticle
  7. Impact of radiotherapy for nasopharyngeal carcinoma on carotid stenosis risk: a meta-analysis2023Figsharedataset
  8. Induction chemotherapy plus radiotherapy alone versus cisplatin-based concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: An open-label, non-inferiority, randomized phase 3 trial.2023Journal of Clinical Oncologyconference-abstract
  9. Additional file 1 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  10. Additional file 2 of CapG promoted nasopharyngeal carcinoma cell motility involving Rho motility pathway independent of ROCK2022Figsharedataset
  11. Additional file 2 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  12. Additional file 3 of CapG promoted nasopharyngeal carcinoma cell motility involving Rho motility pathway independent of ROCK2022Figsharedataset
  13. Additional file 3 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  14. Additional file 4 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  15. Additional file 5 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  16. Additional file 6 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  17. Additional file 7 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  18. Additional file 8 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  19. Additional file 9 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  20. 436 A phase II study of AK104, a bispecific antibody targeting PD-1 and CTLA-4, in patients with metastatic nasopharyngeal carcinoma (NPC) who had progressed after two or more lines of chemotherapy2021Journal for ImmunoTherapy of Cancerconference-abstract

Run the PubMed searchClinicalTrials.gov

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 8 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.3%.

Papers led
8
2021–2025
Trials led
6
any status, ClinicalTrials.gov
Open trials led
4
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 3320222023: 1120232024: 1120242025: 112025

11 hospitals in Guangzhou for oesophageal squamous cell carcinoma191 hospitals in China for oesophageal squamous cell carcinoma

Open trials with this hospital 4

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Efficacy and Safety of Anlotinib Combined With Bemocizumab for Neoadjuvant Therapy of Esophageal Squamous Cell Carcinoma(ESCC)
    Phase
    N/A
    Started
    2026-05
    Registry
    NCT07627347

    Age 18 years to 70 years (registered criteria)

    Led by Nanfang HospitalGuangzhou

  2. Recruiting
    A Phase II Study of Toripalimab Combined With Sequential Neoadjuvant Chemoradiotherapy in Patients With Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2025-04
    Registry
    NCT06843889

    Age 18 years to 75 years (registered criteria)

    Led by Nanfang HospitalGuangzhou

  3. Recruiting
    Penpulimab Plus Chemotherapy With/Without Anlotinib for Patients With Advanced Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2022-09
    Registry
    NCT05214222

    Age 18 years to 75 years (registered criteria)

    Led by Nanfang HospitalGuangzhou

  4. Recruiting
    Immune Indicator Model for Predicting Efficacy of PD-1 Monoclonal Antibody
    Phase
    Not given
    Started
    2022-08
    Registry
    NCT05392413

    Age 18 years to 75 years (registered criteria)

    Led by Nanfang HospitalGuangzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesMolecular markers & genomicsEarly detection & endoscopy
Departments in papersPathology / laboratory medicineGastroenterology / hepatologyRadiation oncology

Over half of these papers are lab or animal studies.

Papers it led8
  1. High Kin17 expression is correlated with metastasis and prognosis of esophageal squamous cell carcinoma.2025The International journal of biological markers
  2. Global burden of esophageal cancer attributable to high BMI in 204 countries and territories: 1990-2019.2024Thoracic cancerFree full text
  3. Plasma cell-free DNA 5-hydroxymethylcytosine and whole-genome sequencing signatures for early detection of esophageal cancer.2023Cell death & diseaseFree full text
  4. COX-2 strengthens the effects of acid and bile salts on human esophageal cells and Barrett esophageal cells.2022BMC molecular and cell biologyFree full text
  5. High-throughput membrane-anchored proteome screening reveals PIEZO1 as a promising antibody-drug target for human esophageal squamous cell carcinoma.2022Cancer medicineFree full text
  6. Reticulocalbin3: A Ca2+ homeostasis regulator that promotes esophageal squamous cell carcinoma progression and cisplatin resistance.2022Cancer scienceFree full text
  7. Oesophageal squamous cell carcinoma-associated IL-33 rewires macrophage polarization towards M2 via activating ornithine decarboxylase.2021Cell proliferationFree full text
  8. Upregulated long non‑coding RNA LincIN promotes tumor progression via the regulation of nuclear factor 90/microRNA‑7/HOXB13 in esophageal squamous cell carcinoma.2021International journal of molecular medicineFree full text
All its trials on ClinicalTrials.gov, any status11
  1. Efficacy and Safety of Anlotinib Combined With Bemocizumab for Neoadjuvant Therapy of Esophageal Squamous Cell Carcinoma(ESCC)RecruitingNCT07627347Lead sponsorN/AStart 2026-05
  2. A Phase II Study of Toripalimab Combined With Sequential Neoadjuvant Chemoradiotherapy in Patients With Esophageal Squamous Cell CarcinomaRecruitingNCT06843889Lead sponsorPhase 2Start 2025-04
  3. Penpulimab Plus Chemotherapy With/Without Anlotinib for Patients With Advanced Esophageal Squamous Cell CarcinomaRecruitingNCT05214222Lead sponsorPhase 2Start 2022-09
  4. Immune Indicator Model for Predicting Efficacy of PD-1 Monoclonal AntibodyRecruitingNCT05392413Lead sponsorStart 2022-08
  5. Efficacy and Safety of Adebrelimab Combined With Chemoradiotherapy in Patients With Unresectable Locally Advanced or Postoperative Recurrent Esophageal Squamous Cell CarcinomaActive, not recruitingNCT06885814Lead sponsorPhase 2Start 2024-06
  6. Exploration and Verification of DNA Methylolation in Early Screening of Esophageal CancerStatus unknownNCT03922230Lead sponsorStart 2019-03
  7. Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell CarcinomaCompletedNCT04732494Study sitePhase 2Start 2021-03
  8. Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014).TerminatedNCT04949256Study sitePhase 3Start 2021-07
  9. A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent ChemoradiotherapyCompletedNCT04543617Study sitePhase 3Start 2020-09
  10. A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal CarcinomaCompletedNCT04540211Study sitePhase 3Start 2020-10
  11. The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCCStatus unknownNCT02915432Study sitePhase 1/Phase 2Start 2016-12
More papers found outside PubMed (not counted)10
  1. A phase II trial of neoadjuvant chemotherapy combined with anti-angiogenesis therapy and immunotherapy for resectable stageII-IIIB esophageal squamous cell carcinoma.2025Journal of Clinical Oncologyarticle
  2. Comparative genomic analysis of tumor tissue and surgical margin distances in esophageal squamous cell carcinoma.2025Journal of Clinical Oncologyarticle
  3. FGF19-FGFR4 axis as the inaugural target for determining the efficacy of advanced esophageal cancer treatment.2024Journal of Clinical Oncologyconference-abstract
  4. Impact of positive tumor-informed margin and TP53 mutations on surgical outcomes in esophageal squamous cell carcinoma.2024Journal of Clinical Oncologyconference-abstract
  5. Penpulimab plus chemotherapy with or without anlotinib as first-line treatment for patients with advanced esophageal squamous cell carcinoma (ANSWER): A randomized, two-arm, clinical trial in progress.2023Journal of Clinical Oncologyconference-abstract
  6. 429. DETECTION OF MOLECULAR RESIDUAL DISEASE (MRD) USING MATCHED TUMOR-MARGIN SEQUENCING IN EARLY STAGE ESOPHAGEAL SQUAMOUS CELL CARCINOMA2022Diseases of the Esophagusarticle
  7. Additional file 1 of OTUB2 Regulates YAP1/TAZ to Promotes the Progression of Esophageal Squamous Cell Carcinoma2022Figsharedataset
  8. Additional file 7 of Heparanase is a prognostic biomarker independent of tumor purity and hypoxia based on bioinformatics and immunohistochemistry analysis of esophageal squamous cell carcinoma2022Figsharedataset
  9. Abstract 2178: Spectrum of pathogenic germline mutations in Chinese esophageal squamous cell carcinoma patients through next-generation sequencing2021Cancer Researchconference-abstract
  10. Three Survival‐Related Genes of Esophageal Squamous Cell Carcinoma Identified by Weighted Gene Coexpression Network Analysis2021Complexityarticle

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 127 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.9%.

Papers led
127
2021–2025
Trials led
15
any status, ClinicalTrials.gov
Open trials led
7
recruiting or about to
Open trials as a site
4
led by another institution
Papers led per year
2021: 242420212022: 333320222023: 242420232024: 191920242025: 25252025

14 hospitals in Guangzhou for hepatocellular carcinoma192 hospitals in China for hepatocellular carcinoma

Open trials with this hospital 11

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    QL1706 in Combination With Bevacizumab and RALOX HAIC for Hepatocellular Carcinoma With Vp3/4 PVTT
    Phase
    Phase 2
    Started
    2025-12
    Registry
    NCT07327788

    Age 18 years to Not stated (registered criteria)

    Led by Nanfang HospitalGuangzhou

  2. Recruiting
    Impact of Emotional Status on Prognosis of Patients With BCLC Stage B/C Hepatocellular Carcinoma Undergoing Hepatic Arterial Infusion Chemotherapy Combined With Targeted and Immunotherapy
    Phase
    Not given
    Started
    2025-12
    Registry
    NCT07436845

    Age 18 years to Not stated (registered criteria)

    Led by Nanfang HospitalGuangzhou

  3. Recruiting
    Correlation Study of Lipid Metabolites as Markers of Hepatocellular Carcinoma
    Phase
    Not given
    Started
    2024-07
    Registry
    NCT06623474

    Age 18 years to 80 years (registered criteria)

    Led by Nanfang HospitalGuangzhou

  4. Recruiting
    Plasma Sphingolipid Metabolites and Radiotherapy Efficacy in Hepatocellular Carcinoma
    Phase
    Not given
    Started
    2024-09
    Registry
    NCT06864221

    Age 18 years to 80 years (registered criteria)

    Led by Nanfang HospitalGuangzhou

  5. Not yet recruiting
    Benmelstobart Plus Anlotinib Combined With SBRT for Patients With Hepatocellular Carcinoma Failing First-Line Targeted Therapy
    Phase
    Phase 2
    Started
    2026-04
    Registry
    NCT07537777

    Age 18 years to Not stated (registered criteria)

    Led by Nanfang HospitalGuangzhou

  6. Not yet recruiting
    Nanocrystalline Megestrol Acetate Versus Placebo for Anorexia in Patients With Unresectable Hepatocellular Carcinoma Receiving TACE Combined With Targeted and Immunotherapy
    Phase
    Phase 2
    Started
    2026-06
    Registry
    NCT07565415

    Age 18 years to Not stated (registered criteria)

    Led by Nanfang HospitalGuangzhou

  7. Enrolling by invitation
    A Multicenter Prospective Observational Study of Computer-aided Risk Perception and Prognosis Prediction in the Whole Process of Laparoscopic Hepatobiliary and Pancreatic Surgery
    Phase
    Not given
    Started
    2024-09
    Registry
    NCT06647264

    Age 18 years to 80 years (registered criteria)

    Led by Nanfang HospitalGuangzhou

  8. Recruiting
    A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC
    Phase
    Phase 1/Phase 2
    Started
    2026-05
    Registry
    NCT07547553

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Bengbu, Changchun, Fuzhou, Guangzhou, Harbin, Hefei, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Tianjin

  9. Recruiting
    A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)
    Phase
    Phase 1
    Started
    2025-04
    Registry
    NCT06858813

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesGuangzhou, Shanghai

  10. Recruiting
    Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
    Phase
    Phase 1
    Started
    2025-11
    Registry
    NCT07176650

    Age 18 years to 65 years (registered criteria)

    Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Bengbu, Changchun, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Hefei, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Xi'an, Zhengzhou

  11. Recruiting
    A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2024-07
    Registry
    NCT06427941

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 16 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Nanchang, Nanning, Shijiazhuang, Wenzhou, Wuhan, Xuzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRecurrence & prognosisImmunotherapy & targeted drugsImaging, AI & early detection
Departments in papersRadiation oncologyGastroenterology / hepatologySurgery (general/hepatobiliary/pancreatic)Radiology / nuclear medicine
Papers it led127
  1. Three-dimensional multimodal imaging for predicting early recurrence of hepatocellular carcinoma after surgical resection.2026Journal of advanced researchFree full text
  2. A Novel Diagnostic Algorithm for Subcentimeter Hepatocellular Carcinoma Utilizing Gd-EOB-DTPA-Enhanced MRI: Multicenter Development and Validation.2025Academic radiology
  3. Acute kidney injury is associated with liver-related outcomes in patients with hepatitis B virus infection: a retrospective cohort study.2025BMC nephrologyFree full text
  4. The safety and feasibility of the "pan-gate theory" in laparoscopic liver resection through laennec's approach combined with "regional hepatic inflow occlusion" for hepatocellular carcinoma.2025BMC surgeryFree full text
  5. Baicalin promotes anti-tumor immunity in hepatocellular carcinoma through HIF-1α/Lactate/CXCL9 axis.2025Biochemical pharmacology
  6. PD-1/PD-L1 blockade therapy in hepatocellular carcinoma: Current status and potential biomarkers.2025Biochimica et biophysica acta. Reviews on cancer
  7. BAIAP2L2 facilitates hepatocellular carcinoma progression and immune evasion of via targeting JAK1-mediated pathway and PD-L1 expression.2025Cancer gene therapy
  8. Histopathologic deep learning model for predicting tumor response to hepatic arterial infusion chemotherapy plus TKIs and ICIs in large hepatocellular carcinoma.2025Cancer imaging : the official publication of the International Cancer Imaging SocietyFree full text
  9. TCR-based cellular immunotherapy for hepatocellular carcinoma: advances, challenges, and prospects.2025Cancer immunology, immunotherapy : CIIFree full text
  10. SORT1 promote the metastasis and invasion of hepatocellular carcinoma via p38/β-catenin/ZEB1 signaling pathway.2025Cell death & diseaseFree full text
  11. Spermine synthase engages in macrophages M2 polarization to sabotage antitumor immunity in hepatocellular carcinoma.2025Cell death and differentiationFree full text
  12. Role of Early On-Treatment Serum HBV RNA Declines in Predicting Hepatocellular Carcinoma Risk in Patients With Chronic Hepatitis B.2025Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  13. Association of daily sleep duration with risk of metabolic dysfunction-associated steatotic liver disease and adverse liver outcomes.2025Diabetes & metabolism
  14. The oncogenic role of BCL2L12 associated with immune status in the prognosis of human hepatocellular carcinoma.2025Die Naturwissenschaften
  15. Metabolomics and lipidomics predictor of survival in hepatocellular carcinoma patients receiving tyrosine kinase inhibitor and immune checkpoint inhibitor combination therapy.2025Drug metabolism and disposition: the biological fate of chemicals
  16. The LUBAC subunit HOIL-1 promotes the progression of HBV-associated hepatocellular carcinoma independently of linear ubiquitination.2025Experimental & molecular medicineFree full text
  17. Integration of Bulk RNA and Single-Cell Analyses Reveal Distinct Expression Patterns of Anoikis-Related Genes and the Immunosuppressive Role of NQO1+ Macrophages in Hepatocellular Carcinoma.2025FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  18. Matching-adjusted indirect comparison of tislelizumab plus lenvatinib versus sintilimab plus bevacizumab biosimilar as first-line treatment for unresectable hepatocellular carcinoma.2025Frontiers in immunologyRCTFree full text
  19. Quantification of Fascin-1-Positive Extracellular Vesicles by Nanoflow Cytometry for Early Detection of Hepatocellular Carcinoma in Liquid Biopsy.2025International journal of medical sciencesFree full text
  20. Antiangiogenic Treatment Facilitates the Abscopal Effect of Radiation Therapy Combined With Anti-PD-1 in Hepatocellular Carcinoma.2025International journal of radiation oncology, biology, physics
  21. Comparison of the efficacy and safety of TACE-HAIC-MTTs-ICIs and TACE-MTTs-ICIs in the hepatocellular carcinoma: a prognostic analysis based on the dynamic changes of serum AFP.2025International journal of surgery (London, England)Free full text
  22. Exploring the potential mechanisms of Jinglinzi powder in treating hepatocellular carcinoma based on LC-MS, network pharmacology, molecular docking, and experimental validation.2025Journal of pharmaceutical and biomedical analysis
  23. Preoperative plasma ceramide profiling coupled with machine learning accurately predicts recurrence of hepatocellular carcinoma after resection.2025Lipids in health and diseaseFree full text
  24. Low-Level Viremia Impairs Efficacy of Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma.2025Liver international : official journal of the International Association for the Study of the LiverFree full text
  25. Picropodophyllin induces ferroptosis via blockage of AKT/NRF2/SLC7A11 and AKT/NRF2/SLC40A1 axes in hepatocellular carcinoma as a natural IGF1R inhibitor.2025Phytomedicine : international journal of phytotherapy and phytopharmacology
  26. Dual-Targeting Peptide Assembly Probe for Precise Detection of Biomarkers of Circulating Tumor Cells in Hepatocellular Carcinoma.2025Small (Weinheim an der Bergstrasse, Germany)
  27. Spleen-dedicated stiffness measurement performed well to rule out high-risk varices in HBV-related hepatocellular carcinoma: Screening for high-risk varices in HCC.2024Alimentary pharmacology & therapeutics
  28. Evaluation of an artificial intelligence-based clinical trial matching system in Chinese patients with hepatocellular carcinoma: a retrospective study.2024BMC cancerFree full text
  29. Synthesis and preclinical evaluation of a novel probe [18F]AlF-NOTA-IPB-GPC3P for PET imaging of GPC3 positive tumor.2024Bioorganic chemistry
  30. DYNLL1 accelerates cell cycle via ILF2/CDK4 axis to promote hepatocellular carcinoma development and palbociclib sensitivity.2024British journal of cancerFree full text
  31. Renin-angiotensin system inhibitors and risk of hepatocellular carcinoma among patients with hepatitis B virus infection.2024CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienneFree full text
  32. Endoplasmic Reticulum Stress Potentiates the Immunosuppressive Microenvironment in Hepatocellular Carcinoma by Promoting the Release of SNHG6-Enriched Small Extracellular Vesicles.2024Cancer immunology research
  33. Atovaquone enhances antitumor efficacy of TCR-T therapy by augmentation of ROS-induced ferroptosis in hepatocellular carcinoma.2024Cancer immunology, immunotherapy : CIIFree full text
  34. Identification of pyroptosis subtypes and prognosis model of hepatocellular carcinoma based on pyroptosis-related genes.2024Cancer medicineFree full text
  35. Two somatic mutations in the androgen receptor N-terminal domain are oncogenic drivers in hepatocellular carcinoma.2024Communications biologyFree full text
  36. Effect of peripheral blood lymphocyte count on the efficacy of immunotherapy combined with TKI in the treatment of advanced liver cancer.2024Frontiers in immunologyFree full text
  37. Lactylation signature identifies liver fibrosis phenotypes and traces fibrotic progression to hepatocellular carcinoma.2024Frontiers in immunologyFree full text
  38. Noncanonical regulation of HOIL-1 on cancer stemness and sorafenib resistance identifies pixantrone as a novel therapeutic agent for HCC.2024Hepatology (Baltimore, Md.)
  39. Letter to the Editor: Chronic hepatitis B baseline viral load and on-treatment liver cancer risk: A multinational cohort study of HBeAg-positive patients.2024Hepatology (Baltimore, Md.)
  40. The development of a novel zeolite-based assay for efficient and deep plasma proteomic profiling.2024Journal of nanobiotechnologyFree full text
  41. Radiotherapy enhances the anti-tumor effect of CAR-NK cells for hepatocellular carcinoma.2024Journal of translational medicineFree full text
  42. Relationship among serum 25-hydroxyvitamin D, fibrosis stage, genetic susceptibility, and risk of severe liver disease.2024Nutrition (Burbank, Los Angeles County, Calif.)
  43. Integrative radiomics analyses identify universal signature for predicting prognosis and therapeutic vulnerabilities across primary and secondary liver cancers: A multi-cohort study.2024Pharmacological research
  44. A novel engineered IL-21 receptor arms T-cell receptor-engineered T cells (TCR-T cells) against hepatocellular carcinoma.2024Signal transduction and targeted therapyFree full text
  45. Identification of secretory pathway-related genes based on Random Forest algorithm to predict the prognosis and immunotherapy response of hepatocellular carcinoma.2024The journal of gene medicine
  46. Multiomics analyses and machine learning of nuclear receptor coactivator 6 reveal its essential role in hepatocellular carcinoma.2023Cancer scienceFree full text
  47. Hexokinase 2 confers radio-resistance in hepatocellular carcinoma by promoting autophagy-dependent degradation of AIMP2.2023Cell death & diseaseFree full text
  48. TUBB2B facilitates progression of hepatocellular carcinoma by regulating cholesterol metabolism through targeting HNF4A/CYP27A1.2023Cell death & diseaseFree full text
  49. Thermoresponsive hydrogel for transcatheter arterial chemoembolization of hepatocellular carcinoma.2023Chemical communications (Cambridge, England)
  50. ALKBH5-mediated m6 A demethylation of TIRAP mRNA promotes radiation-induced liver fibrosis and decreases radiosensitivity of hepatocellular carcinoma.2023Clinical and translational medicineFree full text
  51. H4-methylation regulators mediated epitranscriptome patterns and tumor microenvironment infiltration characterization in hepatocellular carcinoma.2023Clinical epigeneticsFree full text
  52. Radiomics signature based on CECT for non-invasive prediction of response to anti-PD-1 therapy in patients with hepatocellular carcinoma.2023Clinical radiology
  53. Safety and efficacy of postoperative adjuvant therapy with atezolizumab and bevacizumab after radical resection of hepatocellular carcinoma.2023Clinics and research in hepatology and gastroenterology
  54. Predictive Value of the Hepatic Immune Predictive Index for Patients with Primary Liver Cancer Treated with Immune Checkpoint Inhibitors.2023Digestive diseases (Basel, Switzerland)
  55. Various ambient air pollutants, residential green spaces, fibrosis 4 scores, genetic susceptibility, and risk of severe liver disease.2023Ecotoxicology and environmental safety
  56. TRMT6 promotes hepatocellular carcinoma progression through the PI3K/AKT signaling pathway.2023European journal of medical researchFree full text
  57. Noninvasive evaluation of neutrophil extracellular traps signature predicts clinical outcomes and immunotherapy response in hepatocellular carcinoma.2023Frontiers in immunologyFree full text
  58. T cell receptor and B cell receptor exhibit unique signatures in tumor and adjacent non-tumor tissues of hepatocellular carcinoma.2023Frontiers in immunologyFree full text
  59. Targeting NAD+ metabolism of hepatocellular carcinoma cells by lenvatinib promotes M2 macrophages reverse polarization, suppressing the HCC progression.2023Hepatology international
  60. Tyrosine kinase inhibitors, immune checkpoint inhibitors combined with hepatic arterial infusion of oxaliplatin and raltitrexed versus oxaliplatin, 5-fluorouracil and leucovorin for intermediate and advanced hepatocellular carcinoma: A retr2023International immunopharmacology
  61. Expression and prognostic signatures of m6A-related lncRNAs in hepatocellular carcinoma.2023Journal of cancer research and clinical oncologyFree full text
  62. Biejiajian pill inhibits progression of hepatocellular carcinoma by downregulating PDGFRβ signaling in cancer-associated fibroblasts.2023Journal of ethnopharmacology
  63. N6-methyladenosine RNA methylation in liver diseases: from mechanism to treatment.2023Journal of gastroenterology
  64. Novel, high accuracy models for hepatocellular carcinoma prediction based on longitudinal data and cell-free DNA signatures.2023Journal of hepatology
  65. HIGD2A silencing impairs hepatocellular carcinoma growth via inhibiting mitochondrial function and the MAPK/ERK pathway.2023Journal of translational medicineFree full text
  66. TRIM16 E121D variant affects the risk and prognosis of hepatocellular carcinoma by modulating the Wnt/β-catenin pathway.2023Molecular carcinogenesis
  67. Baicalin inhibits hepatocellular carcinoma cell growth and metastasis by suppressing ROCK1 signaling.2023Phytotherapy research : PTR
  68. Pien Tze Huang regulates phosphorylation of metabolic enzymes in mice of hepatocellular carcinoma.2023Scientific reportsFree full text
  69. The phospholipid flippase ATP9A enhances macropinocytosis to promote nutrient starvation tolerance in hepatocellular carcinoma.2023The Journal of pathology
  70. Manifold Roles of Ceramide Metabolism in Non-Alcoholic Fatty Liver Disease and Liver Cancer.2022Advances in experimental medicine and biology
  71. Machine-learning algorithms based on personalized pathways for a novel predictive model for the diagnosis of hepatocellular carcinoma.2022BMC bioinformaticsFree full text
  72. A stratification model of hepatocellular carcinoma based on expression profiles of cells in the tumor microenvironment.2022BMC cancerFree full text
  73. Clinical and imaging features preoperative evaluation of histological grade and microvascular infiltration of hepatocellular carcinoma.2022BMC gastroenterologyFree full text
  74. Interaction between baseline HBV loads and the prognosis of patients with HCC receiving anti-PD-1 in combination with antiangiogenic therapy undergoing concurrent TAF prophylaxis.2022BMC infectious diseasesFree full text
  75. NUPR1 contributes to radiation resistance by maintaining ROS homeostasis via AhR/CYP signal axis in hepatocellular carcinoma.2022BMC medicineFree full text
  76. Lamin B1 is a potential therapeutic target and prognostic biomarker for hepatocellular carcinoma.2022BioengineeredFree full text
  77. UBE2T-mediated Akt ubiquitination and Akt/β-catenin activation promotes hepatocellular carcinoma development by increasing pyrimidine metabolism.2022Cell death & diseaseFree full text
  78. A New Prognostic Strategy Based on four DNA Repair-Associated lncRNAs for Hepatocellular Carcinoma.2022Combinatorial chemistry & high throughput screening
  79. Identification of a Novel N7-Methylguanosine-Related LncRNA Signature Predicts the Prognosis of Hepatocellular Carcinoma and Experiment Verification.2022Current oncology (Toronto, Ont.)Free full text
  80. CT images-based 3D convolutional neural network to predict early recurrence of solitary hepatocellular carcinoma after radical hepatectomy.2022Diagnostic and interventional radiology (Ankara, Turkey)Free full text
  81. IVIM using convolutional neural networks predicts microvascular invasion in HCC.2022European radiology
  82. IMPDH1, a prognostic biomarker and immunotherapy target that correlates with tumor immune microenvironment in pan-cancer and hepatocellular carcinoma.2022Frontiers in immunologyFree full text
  83. Akkermansia muciniphila suppressing nonalcoholic steatohepatitis associated tumorigenesis through CXCR6+ natural killer T cells.2022Frontiers in immunologyFree full text
  84. Hepatic Tumor Stiffness Measured by Shear Wave Elastography Is Prognostic for HCC Progression Following Treatment With Anti-PD-1 Antibodies Plus Lenvatinib: A Retrospective Analysis of Two Independent Cohorts.2022Frontiers in immunologyFree full text
  85. Circulating HBV RNA: From biology to clinical applications.2022Hepatology (Baltimore, Md.)
  86. Exploring prognostic value and regulation network of PPP1R1A in hepatocellular carcinoma.2022Human cell
  87. Phosphotungstate Acid Doped Polyanilines Nanorods for in situ NIR-II Photothermal Therapy of Orthotopic Hepatocellular Carcinoma in Rabbit.2022International journal of nanomedicineFree full text
  88. An individualized cirrhosis screening strategy might be more cost-effective in the general population.2022Journal of hepatology
  89. COMMD10 inhibits HIF1α/CP loop to enhance ferroptosis and radiosensitivity by disrupting Cu-Fe balance in hepatocellular carcinoma.2022Journal of hepatology
  90. A Lamin Family-Based Signature Predicts Prognosis and Immunotherapy Response in Hepatocellular Carcinoma.2022Journal of immunology researchFree full text
  91. Downregulation of TUSC3 promotes EMT and hepatocellular carcinoma progression through LIPC/AKT axis.2022Journal of translational medicineFree full text
  92. TGF-β1 induced deficiency of linc00261 promotes epithelial-mesenchymal-transition and stemness of hepatocellular carcinoma via modulating SMAD3.2022Journal of translational medicineFree full text
  93. Short-term prognosis for hepatocellular carcinoma patients with lung metastasis: A retrospective cohort study based on the SEER database.2022MedicineRCTFree full text
  94. Serum SALL4 as a predictive biomarker for the prognosis of patients with hepatocellular carcinoma who underwent nonsurgical treatment.2022MedicineFree full text
  95. The effects of the interactions of STAT4 rs7574865 with HBV mutations on the risk of hepatocellular carcinoma.2022Molecular carcinogenesis
  96. An enhancer variant at 16q22.1 predisposes to hepatocellular carcinoma via regulating PRMT7 expression.2022Nature communicationsFree full text
  97. PBLD inhibits angiogenesis via impeding VEGF/VEGFR2-mediated microenvironmental cross-talk between HCC cells and endothelial cells.2022OncogeneFree full text
  98. Laparoscopic central hepatectomy using a parenchymal-first approach: how we do it.2022Surgical endoscopy
  99. CRIP1 suppresses BBOX1-mediated carnitine metabolism to promote stemness in hepatocellular carcinoma.2022The EMBO journalFree full text
  100. Association of Serum Hepatitis B Virus RNA With Hepatocellular Carcinoma Risk in Chronic Hepatitis B Patients Under Nucleos(t)ide Analogues Therapy.2022The Journal of infectious diseases
  101. PPP2R5D promotes hepatitis C virus infection by binding to viral NS5B and enhancing viral RNA replication.2022Virology journalFree full text
  102. Tumor-feeding artery diameter reduction is associated with improved short-term effect of hepatic arterial infusion chemotherapy plus lenvatinib treatment.2022World journal of gastroenterologyFree full text
  103. Identification of RNA binding protein interacting with circular RNA and hub candidate network for hepatocellular carcinoma.2021AgingFree full text
  104. Editorial: central obesity is a risk factor for hepatocellular carcinoma in Asian patients with chronic hepatitis B on anti-viral therapy-authors' reply.2021Alimentary pharmacology & therapeutics
  105. DEAH-box polypeptide 32 promotes hepatocellular carcinoma progression via activating the β-catenin pathway.2021Annals of medicineFree full text
  106. Identification of a thirteen-gene signature predicting overall survival for hepatocellular carcinoma.2021Bioscience reportsFree full text
  107. ACOX2 is a prognostic marker and impedes the progression of hepatocellular carcinoma via PPARα pathway.2021Cell death & diseaseFree full text
  108. Medical ozone induces proliferation and migration inhibition through ROS accumulation and PI3K/AKT/NF-κB suppression in human liver cancer cells in vitro.2021Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  109. COMMD10 inhibits tumor progression and induces apoptosis by blocking NF-κB signal and values up BCLC staging in predicting overall survival in hepatocellular carcinoma.2021Clinical and translational medicineFree full text
  110. The PPRD score stratifies patients with hepatocellular carcinoma and portal vein tumor thrombus treated with sorafenib plus transarterial chemoembolization.2021European radiology
  111. Immunotherapy for Hepatocellular Carcinoma: Current Status and Future Prospects.2021Frontiers in immunologyFree full text
  112. High L-Carnitine Levels Impede Viral Control in Chronic Hepatitis B Virus Infection.2021Frontiers in immunologyFree full text
  113. Increased hepatitis B virus quasispecies diversity is correlated with liver fibrosis progression.2021Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases
  114. Efficacy of sorafenib combined with transcatheter hepatic arterial chemoembolization in treating intermediate-advanced hepatocellular carcinoma.2021Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  115. RNA-binding protein RBM6 acts as a tumor suppressor gene to inhibit the progression of hepatocellular carcinoma.2021Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  116. Programmed cell death-ligand 1 expression in hepatocellular carcinoma and its correlation with clinicopathological characteristics.2021Journal of gastroenterology and hepatologyFree full text
  117. eIF6 promotes the malignant progression of human hepatocellular carcinoma via the mTOR signaling pathway.2021Journal of translational medicineFree full text
  118. The S100 calcium-binding protein A11 promotes hepatic steatosis through RAGE-mediated AKT-mTOR signaling.2021Metabolism: clinical and experimental
  119. NIR-absorbing Prussian blue nanoparticles for transarterial infusion photothermal therapy of VX2 tumors implanted in rabbits.2021Nanoscale
  120. Noninvasively visualize the expression of LAPTM4B protein using a novel 18F-labeled peptide PET probe in hepatocellular carcinoma.2021Nuclear medicine and biology
  121. LIMK1 nuclear translocation promotes hepatocellular carcinoma progression by increasing p-ERK nuclear shuttling and by activating c-Myc signalling upon EGF stimulation.2021Oncogene
  122. Small extracellular vesicles containing miR-30a-3p attenuate the migration and invasion of hepatocellular carcinoma by targeting SNAP23 gene.2021Oncogene
  123. In vitro and in vivo anti-metastatic effect of the alkaliod matrine from Sophora flavecens on hepatocellular carcinoma and its mechanisms.2021Phytomedicine : international journal of phytotherapy and phytopharmacology
  124. Wnt/β-catenin inhibitor ICG-001 enhances the antitumor efficacy of radiotherapy by increasing radiation-induced DNA damage and improving tumor immune microenvironment in hepatocellular carcinoma.2021Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  125. Related Factors of Hepatocellular Carcinoma Recurrence Associated With Hyperglycemia After Liver Transplantation.2021Transplantation proceedings
  126. Development of a computed tomography-based radiomics nomogram for prediction of transarterial chemoembolization refractoriness in hepatocellular carcinoma.2021World journal of gastroenterologyFree full text
  127. Development and Validation of a Contrast-Enhanced CT-Based Radiomics Nomogram for Prediction of Therapeutic Efficacy of Anti-PD-1 Antibodies in Advanced HCC Patients.2020Frontiers in immunologyFree full text
Chinese-language papers (not in the count)23
  1. [Overexpression of parathyroid hormone-like hormone facilitates hepatocellular carcinoma progression and correlates with adverse outcomes].2025Nan fang yi ke da xue xue bao = Journal of Southern Medical UniversityFree full text
  2. [SLC1A5 overexpression accelerates progression of hepatocellular carcinoma by promoting M2 polarization of macrophages].2025Nan fang yi ke da xue xue bao = Journal of Southern Medical UniversityFree full text
  3. [Overexpression of ubiquitin-conjugating enzyme 2T induces radiotherapy resistance in hepatocellular carcinoma by enriching regulatory T cells in the tumor microenvironment].2024Nan fang yi ke da xue xue bao = Journal of Southern Medical UniversityFree full text
  4. [Dealcoholized red wine inhibits occurrence and progression of hepatocellular carcinoma possibly by inducing cell cycle arrest and apoptosis].2023Nan fang yi ke da xue xue bao = Journal of Southern Medical UniversityFree full text
  5. [Study on the comparison of postoperative liver injury caused by hepatic arterial perfusion chemotherapy combined with targeted immunotherapy with hepatic arterial chemoembolization combined with targeted immunotherapy for intermediate-and 2023Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
  6. [Treat-all: challenges of partial response and low-level viremia].2023Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
  7. [Predictive value of aMAP risk score for early recurrence of small hepatocellular carcinoma after microwave ablation].2023Zhonghua nei ke za zhi
  8. [Pan-cancer analysis of the expression pattern of long non-coding RNA MIR22HG].2022Nan fang yi ke da xue xue bao = Journal of Southern Medical UniversityFree full text
  9. [TRIM21 suppresses invasion of hepatocellular carcinoma cells by promoting β-catenin ubiquitylation and degradation].2022Nan fang yi ke da xue xue bao = Journal of Southern Medical UniversityFree full text
  10. [Application of liquid biopsy in early screening and recurrence prediction of hepatocellular carcinoma].2022Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
  11. [Research advances of metabolomics in early diagnosis of hepatocellular carcinoma].2022Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
  12. [Multi-omics research contributes to early screening, diagnosis and treatment of liver cancer].2022Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
  13. [Study on the relationship between nonalcoholic fatty liver disease and hepatocellular carcinoma in patients with prior hepatitis B virus infection].2022Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
  14. [Antitumor effects of AZD2014, a dual mTORC1/2 inhibitor, against human hepatocellular carcinoma xenograft in nude mice].2021Nan fang yi ke da xue xue bao = Journal of Southern Medical UniversityFree full text
  15. [Risk analysis for hepatocellular carcinoma in patients with chronic hepatitis B-associated cirrhosis complicated by type 2 diabetes mellitus: a 5-year prospective cohort study].2021Nan fang yi ke da xue xue bao = Journal of Southern Medical UniversityFree full text
  16. [Long non-coding RNA UPK1A-AS1 promotes glycolysis in hepatocellular carcinoma cells via stabilization of HIF-1α].2021Nan fang yi ke da xue xue bao = Journal of Southern Medical UniversityFree full text
  17. [Analysis of the effect of microwave ablation in the treatment of small liver cancer].2021Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
  18. [Regulatory effect of molecular targeted drugs on the immune system for liver cancer].2021Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
  19. [Higher proportion of hepatitis B-related hepatocellular carcinoma combined with metabolic diseases in patients receiving antiviral therapy].2021Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
  20. [Application of aMAP score to assess the risk of hepatocarciongenesis in population of chronic liver disease in primary hospitals].2021Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
  21. [Clinical efficacy and safety analysis of camrelizumab combined with apatinib as a second-line therapy for unresectable hepatocellular carcinoma: a multicenter retrospective study].2021Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
  22. [Establishing an integrated hospital-community pyramid for screening and achieving hepatocellular carcinoma early diagnosis and treatment].2021Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
  23. [New progress in the diagnosis and treatment of hepatocellular carcinoma: a decade of grinding sword].2021Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
All its trials on ClinicalTrials.gov, any status57
  1. Benmelstobart Plus Anlotinib Combined With SBRT for Patients With Hepatocellular Carcinoma Failing First-Line Targeted TherapyNot yet recruitingNCT07537777Lead sponsorPhase 2Start 2026-04
  2. Nanocrystalline Megestrol Acetate Versus Placebo for Anorexia in Patients With Unresectable Hepatocellular Carcinoma Receiving TACE Combined With Targeted and ImmunotherapyNot yet recruitingNCT07565415Lead sponsorPhase 2Start 2026-06
  3. QL1706 in Combination With Bevacizumab and RALOX HAIC for Hepatocellular Carcinoma With Vp3/4 PVTTRecruitingNCT07327788Lead sponsorPhase 2Start 2025-12
  4. Impact of Emotional Status on Prognosis of Patients With BCLC Stage B/C Hepatocellular Carcinoma Undergoing Hepatic Arterial Infusion Chemotherapy Combined With Targeted and ImmunotherapyRecruitingNCT07436845Lead sponsorStart 2025-12
  5. A Multicenter Prospective Observational Study of Computer-aided Risk Perception and Prognosis Prediction in the Whole Process of Laparoscopic Hepatobiliary and Pancreatic SurgeryEnrolling by invitationNCT06647264Lead sponsorStart 2024-09
  6. Correlation Study of Lipid Metabolites as Markers of Hepatocellular CarcinomaRecruitingNCT06623474Lead sponsorStart 2024-07
  7. Plasma Sphingolipid Metabolites and Radiotherapy Efficacy in Hepatocellular CarcinomaRecruitingNCT06864221Lead sponsorStart 2024-09
  8. Chemotherapy With the Ralox Regimen Combined With Anlotinib and Penpulimab for Unresectable Hepatocellular CarcinomaActive, not recruitingNCT07746960Lead sponsorEarly phase 1Start 2025-01
  9. Sequential TACE-SBRT Combined With Targeted Immunotherapy for Patients With Intermediate to Advanced Liver CancerActive, not recruitingNCT07230080Lead sponsorStart 2024-09
  10. Donafenib Plus Sintilimab in Combination With TACE in Patients With Unresectable Hepatocellular CarcinomaActive, not recruitingNCT05507632Lead sponsorPhase 2Start 2022-08
  11. Hepatic Arterial Infusion Combined With Lenvatinib and Camrelizumab for Unresectable Hepatocellular CarcinomaCompletedNCT05003700Lead sponsorPhase 2Start 2021-08
  12. Carelizumab Combined With Regorafenib in the Treatment of HCC(CARE-2020)Status unknownNCT04806243Lead sponsorPhase 2Start 2021-05
  13. Camrelizumab in Combination With Apatinib Plus NK Cell for Advanced HCCStatus unknownNCT05171309Lead sponsorPhase 2Start 2021-01
  14. Observational Study on Patients With Hepatocellular Carcinoma (HCC)Status unknownNCT04021056Lead sponsorStart 2011-01
  15. Novel Abdominal Compression Positioning Technique for Respiratory Motion Management in Liver TumorsCompletedNCT07745153Lead (inferred)Start 2025-01
  16. A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCCRecruitingNCT07547553Study sitePhase 1/Phase 2Start 2026-05
  17. A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)RecruitingNCT06858813Study sitePhase 1Start 2025-04
  18. Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular CarcinomaRecruitingNCT07176650Study sitePhase 1Start 2025-11
  19. A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid TumorsRecruitingNCT06427941Study sitePhase 1/Phase 2Start 2024-07
  20. A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplimab in Combination With Budigalimab Moves Through the Bodies of Adult Chinese Participants With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC)TerminatedNCT06487559Study sitePhase 1Start 2024-09
  21. A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)Active, not recruitingNCT05904886Study sitePhase 3Start 2023-09
  22. A Phase II Study of AK104 Plus Lenvatinib and TACE in HCCActive, not recruitingNCT05319431Study sitePhase 2Start 2022-06
  23. Auxiliary Diagnosis of Liver Nodules Using cfDNA Whole-genome SignaturesStatus unknownNCT05393102Study siteStart 2022-05
  24. A Trial of Hepatic Arterial Infusion Combined With Apatinib and Camrelizumab Versus Apatinib and Camrelizumab for C-staged Hepatocellular Carcinoma in BCLC ClassificationStatus unknownNCT05313282Study sitePhase 3Start 2022-06
  25. A Trial of Hepatic Arterial Infusion Combined With Bevacizumab and Sintilimab for Unresectable A-staged Hepatocellular Carcinoma in BCLC Classification (D-TRIPLET)Status unknownNCT05214339Study sitePhase 2Start 2022-03
  26. A Study of Amivantamab Monotherapy in Participants With Previously Treated Advanced Hepatocellular CarcinomaTerminatedNCT05653427Study sitePhase 2Start 2022-12
  27. A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular CarcionmaActive, not recruitingNCT04712643Study sitePhase 3Start 2021-03
  28. A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCCCompletedNCT04948697Study sitePhase 2Start 2021-08
  29. A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and BevacizumabActive, not recruitingNCT04770896Study sitePhase 3Start 2021-04
  30. Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004)CompletedNCT04740307Study sitePhase 2Start 2021-03
  31. Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)TerminatedNCT04246177Study sitePhase 3Start 2020-05
  32. "Cocktail" Therapy for Hepatitis B Related Hepatocellular CarcinomaStatus unknownNCT04317248Study sitePhase 2Start 2020-04
  33. Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular CarcinomaCompletedNCT04401800Study sitePhase 2Start 2020-09
  34. Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCCCompletedNCT04723004Study sitePhase 3Start 2020-10
  35. A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCCCompletedNCT03764293Study sitePhase 3Start 2019-06
  36. A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular CarcinomaActive, not recruitingNCT04194775Study sitePhase 3Start 2019-12
  37. A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or AblationCompletedNCT04102098Study sitePhase 3Start 2019-12
  38. Chimeric Antigen Receptor T Cells Targeting Glypican-3CompletedNCT03884751Study sitePhase 1Start 2019-08
  39. A Phase Ib/II Study of Fisogatinib(BLU-554) in Subjects With Hepatocellular CarcinomaCompletedNCT04194801Study sitePhase 1/Phase 2Start 2019-12
  40. Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)CompletedNCT03867084Study sitePhase 3Start 2019-05
  41. A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction CancerCompletedNCT03941873Study sitePhase 1/Phase 2Start 2019-02
  42. Sirolimus-based Immunosuppression Treatment Regimen for Liver TransplantationStatus unknownNCT03500848Study sitePhase 2/Phase 3Start 2018-05
  43. Dual TORC1/TORC2 Inhibitor ATG-008 (CC-223) in HBV Positive Advanced Hepatocellular Carcinoma (HCC) SubjectsTerminatedNCT03591965Study sitePhase 2Start 2018-08
  44. Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)CompletedNCT03713593Study sitePhase 3Start 2018-12
  45. Study of BGB-A317 in Participants With Previously Treated Unresectable HCCCompletedNCT03419897Study sitePhase 2Start 2018-04
  46. Prospective Surveillance for Very Early Hepatocellular CarcinomaStatus unknownNCT03588442Study siteStart 2018-07
  47. A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular CarcinomaCompletedNCT03434379Study sitePhase 3Start 2018-03
  48. A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)CompletedNCT03412773Study sitePhase 3Start 2017-12
  49. The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma SubjectsTerminatedNCT03236649Study sitePhase 3Start 2017-09
  50. The Phase III Study of Icaritin Versus HUACHANSU PIAN in Hepatocellular Carcinoma SubjectsStatus unknownNCT03236636Study sitePhase 3Start 2017-09
  51. A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCCCompletedNCT03516071Study sitePhase 2Start 2017-05
  52. STOPPER CHINA:With Tandem Microspheres in the Treatment of Localized Hepatocellular CarcinomaCompletedNCT03113955Study siteN/AStart 2017-10
  53. HepaSphere Chemoembolization in Advanced HCC Patients: Safety & Efficacy Registry in ChinaStatus unknownNCT02743065Study siteStart 2016-09
  54. A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular CarcinomaCompletedNCT02508467Study sitePhase 1Start 2015-07
  55. Efficacy, Safety, and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular CarcinomaCompletedNCT01988493Study sitePhase 1/Phase 2Start 2014-01
  56. Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC)CompletedNCT00617981Study sitePhase 3Start 2008-05
  57. T138067 Versus Doxorubicin in Chemotherapy-Naive, Unresectable, Hepatocellular Carcinoma PatientsTerminatedNCT00057382Study sitePhase 2/Phase 3Start 2003-03

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 127 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 1.3%.

Papers led
127
2021–2025
Trials led
29
any status, ClinicalTrials.gov
Open trials led
12
recruiting or about to
Open trials as a site
5
led by another institution
Papers led per year
2021: 222220212022: 303020222023: 171720232024: 282820242025: 30302025

16 hospitals in Guangzhou for stomach cancer218 hospitals in China for stomach cancer

Open trials with this hospital 17

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Correlation of Psychological Distress and Immune Checkpoint Inhibitors in Gastric Cancer
    Phase
    Not given
    Started
    2025-01
    Registry
    NCT07003334

    Age 18 years to 75 years (registered criteria)

    Led by Nanfang HospitalGuangzhou

  2. Recruiting
    A Cohort Study of Mobile Capsule Gastroscopy for Gastric Pathologies Screening
    Phase
    Not given
    Started
    2025-06
    Registry
    NCT07032961

    Age 45 years to Not stated (registered criteria)

    Led by Nanfang HospitalGuangzhou

  3. Recruiting
    Novel Humanized Ferritin-Based NIR Fluorescent Probe for Identifying Sentinel Lymph Node Metastasis in Early Gastric Cancer
    Phase
    Not given
    Started
    2025-07
    Registry
    NCT07294638

    Age 18 years to Not stated (registered criteria)

    Led by Nanfang HospitalGuangzhou

  4. Recruiting
    Lenvatinib Plus Tislelizumab and CapeOX as First-Line Treatment for Advanced GC/GEJC With Positive PD-L1 and Low TMEscore
    Phase
    Phase 2
    Started
    2024-06
    Registry
    NCT06157996

    Age 18 years to Not stated (registered criteria)

    Led by Nanfang HospitalGuangzhou

  5. Recruiting
    OGT-assisted Overlap Esophagojejunostomy Versus Traditional Overlap Method
    Phase
    N/A
    Started
    2022-09
    Registry
    NCT05450835

    Age 18 years to 75 years (registered criteria)

    Led by Nanfang Hospital; 7 listed hospitals as study sitesChangchun, Changsha, Guangzhou, Shantou, Shenyang

  6. Recruiting
    Dual-Port Laparoscopic Distal Gastrectomy for Gastric Cancer
    Phase
    N/A
    Started
    2022-08
    Registry
    NCT05494086

    Age 18 years to 75 years (registered criteria)

    Led by Nanfang HospitalGuangzhou

  7. Recruiting
    Relationship Between Perioperative Treatment Efficacy and The Tumor Microenvironment for Locally Advanced Resectable Gastric Cancer.
    Phase
    Not given
    Started
    2021-05
    Registry
    NCT04850729

    Age 18 years to 75 years (registered criteria)

    Led by Nanfang HospitalGuangzhou

  8. Not yet recruiting
    Beta-Blockers on the Efficacy of Neoadjuvant Immunotherapy for Gastric Cancer
    Phase
    Phase 2
    Started
    2026-05
    Registry
    NCT07511894

    Age 18 years to 75 years (registered criteria)

    Led by Nanfang HospitalGuangzhou

  9. Not yet recruiting
    Adaptive Adjuvant Therapy After Neoadjuvant Therapy and Gastrectomy for Gastric or Gastroesophageal Junction Adenocarcinoma
    Phase
    Phase 2/Phase 3
    Started
    2026-06
    Registry
    NCT07603349

    Age 18 years to 75 years (registered criteria)

    Led by Nanfang HospitalGuangzhou

  10. Not yet recruiting
    Novel Humanized Ferritin-based NIR Fluorescent Molecular Probe for Identifying Tumor Margins in Gastric Tissue
    Phase
    Not given
    Started
    2025-12
    Registry
    NCT07276854

    Age 18 years to Not stated (registered criteria)

    Led by Nanfang HospitalGuangzhou

  11. Not yet recruiting
    Neoadjuvant Cadonilimab Plus Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer Trial
    Phase
    Phase 2
    Started
    2024-03
    Registry
    NCT06310473

    Age 18 years to 75 years (registered criteria)

    Led by Nanfang HospitalGuangzhou

  12. Enrolling by invitation
    An Artificial Intelligence Model for Aiding Claudin18.2 Expression Diagnosis in Gastric Adenocarcinoma
    Phase
    Not given
    Started
    2025-10
    Registry
    NCT07274579

    Age 18 years to Not stated (registered criteria)

    Led by Nanfang Hospital; 1 listed hospital as study siteGuangzhou, Jinan

  13. Recruiting
    Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy
    Phase
    Phase 3
    Started
    2026-12
    Registry
    NCT07789184

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 25 listed hospitals as study sitesBeijing, Changchun, Chongqing, Dalian, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Qingdao, Shanghai, Tianjin, Urumqi, Wuhan, Xi'an

  14. Recruiting
    A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2024-07
    Registry
    NCT06427941

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Hefei, Nanchang, Nanning, Shijiazhuang, Wenzhou, Wuhan, Xuzhou

  15. Recruiting
    Prediction of Peritoneal Metastasis for Gastric Cancer Based on Radiomics
    Phase
    Not given
    Started
    2023-01
    Registry
    NCT05722275

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Kunming, Taiyuan, Zhengzhou

  16. Recruiting
    AI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy
    Phase
    Not given
    Started
    2023-09
    Registry
    NCT06035250

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Changsha, Fuzhou, Guangzhou, Kunming, Nanning, Qingdao, Shanghai, Shenyang, Suzhou, Tianjin, Zhengzhou

  17. Recruiting
    Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.
    Phase
    Phase 2
    Started
    2023-11
    Registry
    NCT06155383

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Guangzhou, Harbin, Jinan, Kunming, Xiamen, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesPeritoneal spread & advanced diseaseImmunotherapy & targeted drugsImaging & AI
Departments in papersSurgery (general/hepatobiliary/pancreatic)Medical oncologyGastroenterology / hepatologyPathology / laboratory medicine
Papers it led127
  1. Bimodal In Situ Analyzer for Circular RNA in Extracellular Vesicles Combined with Machine Learning for Accurate Gastric Cancer Detection.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  2. Artificial Intelligence for Predicting HER2 Status of Gastric Cancer Based on Whole-Slide Histopathology Images: A Retrospective Multicenter Study.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  3. Disitamab vedotin plus programmed death-1 inhibitor for pre-treated HER2 overexpressed advanced gastric cancer: a multicentre retrospective real-world study.2025Annals of medicineFree full text
  4. Conversion Surgery After Trastuzumab-Based Chemotherapy and Immunotherapy for Stage IV HER2-Positive Gastric Cancer: A Retrospective Multicenter Cohort Study.2025Annals of surgical oncology
  5. Joint Nasogastric Tube Versus Traditional Decompression Nasogastric Tube to Guided OGT-Overlap Esophagojejunostomy in Laparoscopic Total Gastrectomy: A Randomized Controlled Trial.2025Annals of surgical oncologyRCT
  6. Molecular mechanisms of transmitted endoplasmic reticulum stress mediating immune escape of gastric cancer via PVR overexpression in TAMs.2025Biochimica et biophysica acta. Molecular basis of disease
  7. Association of proteomics with lymph node metastasis in early gastric cancer patients.2025Biochimica et biophysica acta. Molecular basis of disease
  8. Prognostic Performance of the FLAMB Model in Primary Gastric Diffuse Large B-Cell Lymphoma.2025British journal of hospital medicine (London, England : 2005)
  9. Bi-regional and bi-phasic automated machine learning radiomics for defining metastasis to lesser curvature lymph node stations in gastric cancer.2025Cancer imaging : the official publication of the International Cancer Imaging SocietyFree full text
  10. Association of Neuronal Autoantibodies with Overall Survival in Patients with Gastric Cancer.2025Cancer research communicationsFree full text
  11. POU2F1 inhibits miR-29b1/a cluster-mediated suppression of PIK3R1 and PIK3R3 expression to regulate gastric cancer cell invasion and migration.2025Chinese medical journalFree full text
  12. CD44v6-mediated regulation of gastric cancer stem cells: a potential therapeutic target.2025Clinical and experimental medicineFree full text
  13. Noninvasive Assessment of Vascular Endothelial Growth Factor and Prognosis in Gastric Cancer Through Radiomic Features.2025Clinical and translational gastroenterologyFree full text
  14. UBAP2L-driven stress granule formation links oxaliplatin resistance to gastric cancer.2025Communications biologyFree full text
  15. Repurposing of phosphodiesterase-5 inhibitor sildenafil as a therapeutic agent to prevent gastric cancer growth through suppressing c-MYC stability for IL-6 transcription.2025Communications biologyFree full text
  16. First clinical investigation to predict lymphovascular and/or perineural invasion in gastric cancer using 18F-FAPI-42 PET/CT parameters.2025European journal of nuclear medicine and molecular imaging
  17. Impact of nutrition, comorbidity and complication on long term survival in gastric cancer following laparoscopic radical gastrectomy: A 10-year cohort study.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  18. Identification of a stromal immunosuppressive barrier orchestrated by SPP1+/C1QC+ macrophages and CD8+ exhausted T cells driving gastric cancer immunotherapy resistance.2025Frontiers in immunologyFree full text
  19. The alkylglycerone phosphate synthase sustains the resistance of gastric cancer cells to ferroptosis induced by Apatinib.2025Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  20. PFKFB3 confers cisplatin resistance in gastric cancer by inhibiting ferroptosis through SLC7A11/xCT dephosphorylation.2025International immunopharmacology
  21. Targeting the NAT10/XIST/YAP1 Axis-Mediated Vascular Abnormalization Enhances Immune Checkpoint Blockade in Gastric Cancer.2025International journal of biological sciencesFree full text
  22. Identification the Cellular Senescence Associated lncRNA LINC01579 in Gastric Cancer.2025Journal of cellular and molecular medicineFree full text
  23. Imaging Characteristics and Clinical Outcomes in Gastric Cancer with Brain Metastasis: A Propensity Score-Matched Study.2025Journal of gastrointestinal cancer
  24. HOXA9 drives lymphatic metastasis by activating the c-MYC-glycolysis-lactate axis in gastric cancer.2025Journal of translational medicineFree full text
  25. Computational pathology approach for assessment of prognosis and immunotherapy response in pan-gastrointestinal cancer.2025Journal of translational medicineFree full text
  26. N6-methyladenosine RNA modified BAIAP2L2 facilitates extracellular vesicles-mediated chemoresistance transmission in gastric cancer.2025Journal of translational medicineFree full text
  27. Long non-coding RNA-MIR181A1HG acts as an oncogene and contributes to invasion and metastasis in gastric cancer.2025OncogeneFree full text
  28. Dynamic key vascular anatomy dataset for D2 lymph node dissection during laparoscopic gastric cancer surgery.2025Scientific dataFree full text
  29. Biomimetic Cascade Nanozyme Catalytic System for the Treatment of Lymph Node Metastasis in Gastric Cancer.2025Small (Weinheim an der Bergstrasse, Germany)
  30. Comparison between cap-aspiration lumpectomy versus endoscopic submucosal dissection for the treatment of small gastric submucosal tumors: a prospective randomized controlled trial.2025Surgical endoscopy
  31. Data-Driven Design of Triple-Targeted Protein Nanoprobes for Multiplexed Imaging of Cancer Lymphatic Metastasis.2024Advanced materials (Deerfield Beach, Fla.)
  32. ASO Author Reflections: Preoperative Noninvasive Prediction of Peritoneal Metastasis in Advanced Gastric Cancer: A 18F-FDG PET/CT Radiomics-Based Multimodality Fusion Model.2024Annals of surgical oncology
  33. 18F-FDG PET/CT Radiomics-Based Multimodality Fusion Model for Preoperative Individualized Noninvasive Prediction of Peritoneal Metastasis in Advanced Gastric Cancer.2024Annals of surgical oncology
  34. Screening and identification of vascular endothelial cell targeting peptide in gastric cancer through novel integrated in vitro and in vivo strategy.2024BMC cancerFree full text
  35. Long-term relative survival of patients with gastric cancer from a large-scale cohort: a period-analysis.2024BMC cancerFree full text
  36. FPR3 reprograms glycolytic metabolism and stemness in gastric cancer via calcium-NFATc1 pathway.2024Cancer letters
  37. Cdc42-driven endosomal cholesterol transport promotes collateral resistance in HER2-positive gastric cancer.2024Cancer letters
  38. Dynamic single-cell sequencing unveils the tumor microenvironment evolution of gastric cancer abdominal wall metastases during radiotherapy.2024Cancer scienceFree full text
  39. HMGB1 in exosomes derived from gastric cancer cells induces M2-like macrophage polarization by inhibiting the NF-κB signaling pathway.2024Cell biology international
  40. POLQ inhibition attenuates the stemness and ferroptosis resistance in gastric cancer cells via downregulation of dihydroorotate dehydrogenase.2024Cell death & diseaseFree full text
  41. Nicotinamide metabolism face-off between macrophages and fibroblasts manipulates the microenvironment in gastric cancer.2024Cell metabolism
  42. LINC02139 interacts with and stabilizes XIAP to regulate cell proliferation and apoptosis in gastric cancer.2024Communications biologyFree full text
  43. VENet: Variational energy network for gland segmentation of pathological images and early gastric cancer diagnosis of whole slide images.2024Computer methods and programs in biomedicine
  44. Long-term outcomes of endoscopic therapy versus surgical resection for 2-5 cm gastric gastrointestinal stromal tumors: A population-based comparative study.2024European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  45. Helicobacter pylori CagA-mediated ether lipid biosynthesis promotes ferroptosis susceptibility in gastric cancer.2024Experimental & molecular medicineFree full text
  46. N6-methyladenosine modification of OIP5-AS1 promotes glycolysis, tumorigenesis, and metastasis of gastric cancer by inhibiting Trim21-mediated hnRNPA1 ubiquitination and degradation.2024Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer AssociationFree full text
  47. Multitask machine learning-based tumor-associated collagen signatures predict peritoneal recurrence and disease-free survival in gastric cancer.2024Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  48. Recurrent RhoGAP gene fusion CLDN18-ARHGAP26 promotes RHOA activation and focal adhesion kinase and YAP-TEAD signalling in diffuse gastric cancer.2024GutFree full text
  49. Gut microbiota modulate CD8+ T cell immunity in gastric cancer through Butyrate/GPR109A/HOPX.2024Gut microbesFree full text
  50. SCD1 promotes the stemness of gastric cancer stem cells by inhibiting ferroptosis through the SQLE/cholesterol/mTOR signalling pathway.2024International journal of biological macromolecules
  51. Development and interpretation of a pathomics-driven ensemble model for predicting the response to immunotherapy in gastric cancer.2024Journal for immunotherapy of cancerFree full text
  52. Mutual exclusivity and co-occurrence patterns of immune checkpoints indicate NKG2A relates to anti-PD-1 resistance in gastric cancer.2024Journal of translational medicineFree full text
  53. Tumor microenvironment RNA test to predict immunotherapy outcomes in advanced gastric cancer: The TIMES001 trial.2024Med (New York, N.Y.)
  54. BST2 promotes gastric cancer metastasis under the regulation of HOXD9 and PABPC1.2024Molecular carcinogenesis
  55. Epstein-Barr virus deubiquitinating enzyme BPLF1 is involved in EBV carcinogenesis by affecting cellular genomic stability.2024Neoplasia (New York, N.Y.)Free full text
  56. Lactate/GPR81 recruits regulatory T cells by modulating CX3CL1 to promote immune resistance in a highly glycolytic gastric cancer.2024OncoimmunologyFree full text
  57. Comprehensive assessment of immune context and immunotherapy response via noninvasive imaging in gastric cancer.2024The Journal of clinical investigationFree full text
  58. Macrophage-derived cathepsin L promotes epithelial-mesenchymal transition and M2 polarization in gastric cancer.2024World journal of gastroenterologyFree full text
  59. N4-Acetylcytidine Drives Glycolysis Addiction in Gastric Cancer via NAT10/SEPT9/HIF-1α Positive Feedback Loop.2023Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  60. Safety and Efficacy of OGT-Assisted Overlap Oesophagojejunostomy Versus the Traditional Overlap Method in Laparoscopic Total Gastrectomy for Gastric/Gastroesophageal Junction (G/GEJ) Tumours.2023Annals of surgical oncology
  61. ASO Author Reflections: OGT-Assisted Method Made the Overlap Esophagojejunostomy in Laparoscopic Total Gastrectomy Easier.2023Annals of surgical oncology
  62. Development and validation of nomogram of peritoneal metastasis in gastric cancer based on simplified clinicopathological features and serum tumor markers.2023BMC cancerFree full text
  63. Glutamine metabolic microenvironment drives M2 macrophage polarization to mediate trastuzumab resistance in HER2-positive gastric cancer.2023Cancer communications (London, England)Free full text
  64. Subsite-specific metastatic organotropism and risk in gastric cancer: A population-based cohort study of the US SEER database and a Chinese single-institutional registry.2023Cancer medicineFree full text
  65. The HOXD9-mediated PAXIP1-AS1 regulates gastric cancer progression through PABPC1/PAK1 modulation.2023Cell death & diseaseFree full text
  66. Non-invasive tumor microenvironment evaluation and treatment response prediction in gastric cancer using deep learning radiomics.2023Cell reports. MedicineFree full text
  67. The LINC00501-HSP90B1-STAT3 positive feedback loop promotes malignant behavior in gastric cancer cells.2023Cellular signalling
  68. Molecular mechanism of XB130 adaptor protein mediates trastuzumab resistance in gastric cancer.2023Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  69. Non-invasive CT imaging biomarker to predict immunotherapy response in gastric cancer: a multicenter study.2023Journal for immunotherapy of cancerFree full text
  70. Co-expression pattern of SLC transporter genes associated with the immune landscape and clinical outcomes in gastric cancer.2023Journal of cellular and molecular medicineFree full text
  71. Predicting response to immunotherapy in gastric cancer via assessing perineural invasion-mediated inflammation in tumor microenvironment.2023Journal of experimental & clinical cancer research : CRFree full text
  72. Intensive Systematic "Train-the-Trainer" Course as an Effective Strategy to Improve Detection of Early Gastric Cancer: A Multicenter Retrospective Study.2023Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  73. Multi-modal analysis for accurate prediction of preoperative stage and indications of optimal treatment in gastric cancer.2023La Radiologia medica
  74. Epigenetic Modification-Associated Molecular Classification of Gastric Cancer.2023Laboratory investigation; a journal of technical methods and pathology
  75. Clinicopathological significance of  Obg-like ATPase 1 and its association with Snail in gastric cancer.2023Polish journal of pathology : official journal of the Polish Society of Pathologists
  76. Raltitrexed regulates proliferation and apoptosis of HGC-27 cells by upregulating RSK4.2022BMC pharmacology & toxicologyFree full text
  77. Inhibition of PFKFB3 in HER2-positive gastric cancer improves sensitivity to trastuzumab by inducing tumour vessel normalisation.2022British journal of cancerFree full text
  78. Disrupting Circadian Rhythm via the PER1-HK2 Axis Reverses Trastuzumab Resistance in Gastric Cancer.2022Cancer researchFree full text
  79. PAK6 promotes homologous-recombination to enhance chemoresistance to oxaliplatin through ATR/CHK1 signaling in gastric cancer.2022Cell death & diseaseFree full text
  80. Diabetes mellitus promoted lymph node metastasis in gastric cancer: a 15-year single-institution experience.2022Chinese medical journalFree full text
  81. Endoscopic resection via antral submucosal tunneling for en bloc removal of tumors in the duodenal bulb.2022Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society
  82. Manganese-containing polydopamine nanoparticles as theranostic agents for magnetic resonance imaging and photothermal/chemodynamic combined ferroptosis therapy treating gastric cancer.2022Drug deliveryFree full text
  83. Landscape of exitrons in gastric cancer.2022EBioMedicineFree full text
  84. Circulating tumor cell-associated white blood cell cluster is associated with poor survival of patients with gastric cancer following radical gastrectomy.2022European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  85. Disruption of the CCDC43-FHL1 interaction triggers apoptosis in gastric cancer cells.2022Experimental cell research
  86. Safety and short-term outcomes of laparoscopic surgery for advanced gastric cancer after neoadjuvant immunotherapy: A retrospective cohort study.2022Frontiers in immunologyFree full text
  87. Prognostic characteristics and clinical response to immunotherapy targeting programmed cell death 1 for patients with advanced gastric cancer with liver metastases.2022Frontiers in immunologyFree full text
  88. Tumor Microenvironment Characterization for Assessment of Recurrence and Survival Outcome in Gastric Cancer to Predict Chemotherapy and Immunotherapy Response.2022Frontiers in immunologyFree full text
  89. Relationship Between Programmed Death Ligand 1 Expression and Other Clinicopathological Features in a Large Cohort of Gastric Cancer Patients.2022Frontiers in immunologyFree full text
  90. Application value of overlap guiding tube (OGT) in assisting overlap esophagojejunostomy during laparoscopic total gastrectomy for gastric/gastroesophageal junction (G/GEJ) tumors.2022Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer AssociationFree full text
  91. Tumor-Targeted Polydopamine-Based Nanoparticles for Multimodal Mapping Following Photothermal Therapy of Metastatic Lymph Nodes.2022International journal of nanomedicineFree full text
  92. An artificial intelligence model to predict survival and chemotherapy benefits for gastric cancer patients after gastrectomy development and validation in international multicenter cohorts.2022International journal of surgery (London, England)
  93. Laparoscopic Gastrectomy for Locally Advanced Gastric Cancer-Reply.2022JAMA surgery
  94. Identification of Malassezia globosa as a Gastric Fungus Associated with PD-L1 Expression and Overall Survival of Patients with Gastric Cancer.2022Journal of immunology researchFree full text
  95. Effect of Perioperative Interleukin-6 and Tumor Necrosis Factor-α on Long-Term Outcomes in Locally Advanced Gastric Cancer: Results from the CLASS-01 Trial.2022Journal of immunology researchRCTFree full text
  96. Localized DNA tetrahedrons assisted catalytic hairpin assembly for the rapid and sensitive profiling of small extracellular vesicle-associated microRNAs.2022Journal of nanobiotechnologyFree full text
  97. Association of peripheral basophils with tumor M2 macrophage infiltration and outcomes of the anti-PD-1 inhibitor plus chemotherapy combination in advanced gastric cancer.2022Journal of translational medicineFree full text
  98. An artificial intelligence method to assess the tumor microenvironment with treatment outcomes for gastric cancer patients after gastrectomy.2022Journal of translational medicineFree full text
  99. CT-based radiomics nomograms for preoperative prediction of diffuse-type and signet ring cell gastric cancer: a multicenter development and validation cohort.2022Journal of translational medicineFree full text
  100. Interferon-induced transmembrane protein 2 promotes epithelial-mesenchymal transition by activating transforming growth factor-β1/small mother against decapentaplegic 2 signaling in gastric cancer.2022Molecular biology reports
  101. Prognostic and predictive value of a pathomics signature in gastric cancer.2022Nature communicationsFree full text
  102. Noninvasive imaging of the tumor immune microenvironment correlates with response to immunotherapy in gastric cancer.2022Nature communicationsFree full text
  103. The miR-3648/FRAT1-FRAT2/c-Myc negative feedback loop modulates the metastasis and invasion of gastric cancer cells.2022OncogeneFree full text
  104. Advances in Treatment Models of Advanced Gastric Cancer.2022Technology in cancer research & treatmentFree full text
  105. Predicting peritoneal recurrence and disease-free survival from CT images in gastric cancer with multitask deep learning: a retrospective study.2022The Lancet. Digital health
  106. HMGA1 promotes gastric cancer growth and metastasis by transactivating SUZ12 and CCDC43 expression.2021AgingFree full text
  107. Coexpression of HOXA6 and PBX2 promotes metastasis in gastric cancer.2021AgingFree full text
  108. Development and Validation of a Deep Learning CT Signature to Predict Survival and Chemotherapy Benefit in Gastric Cancer: A Multicenter, Retrospective Study.2021Annals of surgery
  109. Yes associated protein 1 promotes resistance to 5-fluorouracil in gastric cancer by regulating GLUT3-dependent glycometabolism reprogramming of tumor-associated macrophages.2021Archives of biochemistry and biophysics
  110. Long noncoding RNA (lncRNA) EIF3J-DT induces chemoresistance of gastric cancer via autophagy activation.2021AutophagyFree full text
  111. Survival analysis of elderly patients over 65 years old with stage II/III gastric cancer treated with adjuvant chemotherapy after laparoscopic D2 gastrectomy: a retrospective cohort study.2021BMC cancerFree full text
  112. Essential meiotic structure-specific endonuclease1 (EME1) promotes malignant features in gastric cancer cells via the Akt/GSK3B/CCND1 pathway.2021BioengineeredFree full text
  113. Depression accelerates gastric cancer invasion and metastasis by inducing a neuroendocrine phenotype via the catecholamine/β2 -AR/MACC1 axis.2021Cancer communications (London, England)Free full text
  114. USP3 promotes gastric cancer progression and metastasis by deubiquitination-dependent COL9A3/COL6A5 stabilisation.2021Cell death & diseaseFree full text
  115. miR-301a-3p induced by endoplasmic reticulum stress mediates the occurrence and transmission of trastuzumab resistance in HER2-positive gastric cancer.2021Cell death & diseaseFree full text
  116. Identification and validation of methylated differentially expressed miRNAs and immune infiltrate profile in EBV-associated gastric cancer.2021Clinical epigeneticsFree full text
  117. A novel through-the-scope twin clip traction-assisted endoscopic submucosal dissection in an in vitro pig stomach model.2021Endoscopy
  118. Apatinib induced ferroptosis by lipid peroxidation in gastric cancer.2021Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  119. Tumor-infiltrating B cell is associated with the control of progression of gastric cancer.2021Immunologic research
  120. Association of Tumor-Associated Collagen Signature With Prognosis and Adjuvant Chemotherapy Benefits in Patients With Gastric Cancer.2021JAMA network openFree full text
  121. Tumor microenvironment evaluation promotes precise checkpoint immunotherapy of advanced gastric cancer.2021Journal for immunotherapy of cancerFree full text
  122. Vitamin-B12-conjugated PLGA-PEG nanoparticles incorporating miR-532-3p induce mitochondrial damage by targeting apoptosis repressor with caspase recruitment domain (ARC) on CD320-overexpressed gastric cancer.2021Materials science & engineering. C, Materials for biological applications
  123. LncRNA CRNDE attenuates chemoresistance in gastric cancer via SRSF6-regulated alternative splicing of PICALM.2021Molecular cancerFree full text
  124. Predicting postoperative peritoneal metastasis in gastric cancer with serosal invasion using a collagen nomogram.2021Nature communicationsFree full text
  125. CRIP1 cooperates with BRCA2 to drive the nuclear enrichment of RAD51 and to facilitate homologous repair upon DNA damage induced by chemotherapy.2021OncogeneFree full text
  126. The Poor Prognosis of Patients with Stage III Gastric Cancer after D2 Dissection Is Mainly due to Lymphatic Metastasis, Especially the Metastasis of No.12a LN: A Nested Case-Control Study.2021Oncology research and treatment
  127. Radiomics signature based on computed tomography images for the preoperative prediction of lymph node metastasis at individual stations in gastric cancer: A multicenter study.2021Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
Chinese-language papers (not in the count)10
  1. [68Ga-DOTATATE and 18F-FDG PET/CT dual-modality imaging enhances precision of staging and treatment decision for gastroenteropancreatic neuroendocrine neoplasms].2025Nan fang yi ke da xue xue bao = Journal of Southern Medical UniversityFree full text
  2. [A retrospective study on the impact of the number of examined lymph nodes on the survival prognosis of patients with N3b gastric cancer].2025Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  3. [Effect of preoperative immune checkpoint inhibitors on reducing residual lymph node metastases in patients with gastric cancer: a retrospective study].2024Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  4. [ARL67156, a small-molecule CD39 inhibitor, enhances natural killer cell cytotoxicity against gastric cancer cells in vitro and in nude mice].2023Nan fang yi ke da xue xue bao = Journal of Southern Medical UniversityFree full text
  5. [Application of intraoperative endoscopic in laparoscopic gastric cancer surgery].2023Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  6. [Cuprous oxide nanoparticles-based photothermal and chemodynamic synergistic therapy inhibits proliferation and migration of gastric cancer cells in vitro].2022Nan fang yi ke da xue xue bao = Journal of Southern Medical UniversityFree full text
  7. [Application and progress of artificial intelligence technology in gastric cancer diagnosis and treatment].2022Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  8. [Safety and effectiveness of esophagojejunostomy through extracorporeal versus intracorporeal methods after laparoscopic total gastrectomy].2022Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  9. [Research progress and prospect of gastric cancer surgery in 2021].2022Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  10. [Shifting paradigm toward minimally invasive gastrectomy for gastric cancer--China's contribution].2021Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
All its trials on ClinicalTrials.gov, any status48
  1. Beta-Blockers on the Efficacy of Neoadjuvant Immunotherapy for Gastric CancerNot yet recruitingNCT07511894Lead sponsorPhase 2Start 2026-05
  2. Adaptive Adjuvant Therapy After Neoadjuvant Therapy and Gastrectomy for Gastric or Gastroesophageal Junction AdenocarcinomaNot yet recruitingNCT07603349Lead sponsorPhase 2/Phase 3Start 2026-06
  3. An Artificial Intelligence Model for Aiding Claudin18.2 Expression Diagnosis in Gastric AdenocarcinomaEnrolling by invitationNCT07274579Lead sponsorStart 2025-10
  4. Novel Humanized Ferritin-Based NIR Fluorescent Probe for Identifying Sentinel Lymph Node Metastasis in Early Gastric CancerRecruitingNCT07294638Lead sponsorStart 2025-07
  5. A Cohort Study of Mobile Capsule Gastroscopy for Gastric Pathologies ScreeningRecruitingNCT07032961Lead sponsorStart 2025-06
  6. Novel Humanized Ferritin-based NIR Fluorescent Molecular Probe for Identifying Tumor Margins in Gastric TissueNot yet recruitingNCT07276854Lead sponsorStart 2025-12
  7. Correlation of Psychological Distress and Immune Checkpoint Inhibitors in Gastric CancerRecruitingNCT07003334Lead sponsorStart 2025-01
  8. Neoadjuvant Cadonilimab Plus Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer TrialNot yet recruitingNCT06310473Lead sponsorPhase 2Start 2024-03
  9. Lenvatinib Plus Tislelizumab and CapeOX as First-Line Treatment for Advanced GC/GEJC With Positive PD-L1 and Low TMEscoreRecruitingNCT06157996Lead sponsorPhase 2Start 2024-06
  10. Dual-Port Laparoscopic Distal Gastrectomy for Gastric CancerRecruitingNCT05494086Lead sponsorN/AStart 2022-08
  11. OGT-assisted Overlap Esophagojejunostomy Versus Traditional Overlap MethodRecruitingNCT05450835Lead sponsorN/AStart 2022-09
  12. Relationship Between Perioperative Treatment Efficacy and The Tumor Microenvironment for Locally Advanced Resectable Gastric Cancer.RecruitingNCT04850729Lead sponsorStart 2021-05
  13. Beta-Blockers on Neoadjuvant Immunochemotherapy for Hypertensive Patients With Gastric CancerActive, not recruitingNCT07622693Lead sponsorStart 2026-05
  14. Capsule Gastric Endoscopy for Gastric Disease Screening in Simulated Home ScenariosCompletedNCT06848400Lead sponsorN/AStart 2025-04
  15. Cadonilimab Plus CapeOX as First-Line Treatment for Advanced GC/GEJC With High TMEscoreStatus unknownNCT06202716Lead sponsorPhase 2Start 2024-04
  16. JNT Versus TNT to Guided OGT-overlap OesophagojejunostomyCompletedNCT06412575Lead sponsorN/AStart 2023-01
  17. Neoadjuvant Immunotherapy and Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer TrialStatus unknownNCT04744649Lead sponsorPhase 2Start 2021-03
  18. Relationship Between Standard Treatment Efficacy and The Tumor Microenvironment in Advanced Gastric CancerStatus unknownNCT04850716Lead sponsorStart 2021-04
  19. A Phase II Study of Carelizumab Combined With Irinotecan and Apatinib of Second-line Treatment for Advanced Gastric CancerStatus unknownNCT04934618Lead sponsorPhase 2Start 2020-05
  20. Safety and Efficacy of OGT Method Versus the Traditional Overlap MethodCompletedNCT05442502Lead sponsorStart 2018-06
  21. Comparison of Endoscopic and Laparoscopic Resection for Small Gastric Gastrointestinal Stromal TumorStatus unknownNCT03471273Lead sponsorN/AStart 2017-09
  22. Radiomics for Prediction of Lymph Node Metastasis in Gastric Cancer(RPLNM)(GIPMCS-1701)Status unknownNCT03488446Lead sponsorStart 2017-08
  23. Enhanced Recovery After Surgery (ERAS) on Laparoscopy-assisted Distal GastrectomyStatus unknownNCT03016026Lead sponsorPhase 2Start 2016-11
  24. Cytoreductive Surgery Combined With HIPEC and Chemotherapy for Gastric Cancer With Peritoneal MetastasisStatus unknownNCT03023436Lead sponsorPhase 3Start 2016-01
  25. Intracorporeal Versus Extracorporeal Roux-en-Y Esophagojejunostomy During Laparoscopic Total Gastrectomy for Gastric CancerStatus unknownNCT02085031Lead sponsorPhase 2Start 2014-04
  26. Laparoscopy-assisted and Open Distal Gastrectomy for Gastric Cancer in the Elderly PatientsStatus unknownNCT02246153Lead sponsorPhase 3Start 2014-09
  27. Multicenter Study on Laparoscopic Distal Subtotal Gastrectomy for Advanced Gastric Cancer (CLASS-01)Status unknownNCT01609309Lead sponsorPhase 3Start 2012-09
  28. Clinicopathological Features and Treatment Strategies for Gastric Epithelial Neoplasm of Fundic-gland Mucosa LineageCompletedNCT07230054Lead sponsorStart 2010-08
  29. Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell LymphomaStatus unknownNCT04058470Lead (inferred)Phase 1/Phase 2Start 2020-04
  30. Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion TherapyRecruitingNCT07789184Study sitePhase 3Start 2026-12
  31. A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid TumorsRecruitingNCT06427941Study sitePhase 1/Phase 2Start 2024-07
  32. Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.RecruitingNCT06155383Study sitePhase 2Start 2023-11
  33. AI Prediction of Gastric Cancer Response to Neoadjuvant ChemotherapyRecruitingNCT06035250Study siteStart 2023-09
  34. Prediction of Peritoneal Metastasis for Gastric Cancer Based on RadiomicsRecruitingNCT05722275Study siteStart 2023-01
  35. A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)Active, not recruitingNCT06356311Study sitePhase 3Start 2024-05
  36. Clinical Study of SHR-1701 Plus Chemotherapy as Perioperative Treatment in Subjects With Gastric CancerTerminatedNCT05149807Study sitePhase 2/Phase 3Start 2022-01
  37. PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric CancerActive, not recruitingNCT05180734Study sitePhase 3Start 2022-02
  38. A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal JunctionCompletedNCT04661150Study sitePhase 2Start 2021-03
  39. A Study to Confirm the Accuracy of Locally Advanced Gastric Cancer DiagnosisStatus unknownNCT04440605Study siteStart 2020-07
  40. Study of Faecal Bacteria Detection in Early Screening and Diagnosis of GCStatus unknownNCT04638959Study siteStart 2019-09
  41. A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction CancerCompletedNCT03941873Study sitePhase 1/Phase 2Start 2019-02
  42. Laparoscopic D2 Distal Gastrectomy Following Neoadjuvant Chemotherapy for Locally Advanced Gastric CancersStatus unknownNCT03468712Study siteN/AStart 2018-03
  43. Study of BGB-290 or Placebo in Participants With Advanced or Inoperable Gastric CancerCompletedNCT03427814Study sitePhase 2Start 2018-07
  44. Study on Laparoscopic Spleen-Preserving No. 10 Lymph Node Dissection for Advanced Gastric CancerStatus unknownNCT02845986Study sitePhase 2Start 2016-09
  45. The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCCStatus unknownNCT02915432Study sitePhase 1/Phase 2Start 2016-12
  46. Efficacy of HIPEC in the Treatment of Locally Advanced Gastric Cancer After radIcal Gastrectomy With D2Status unknownNCT02356276Study sitePhase 3Start 2015-05
  47. A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction CancerCompletedNCT02178956Study sitePhase 3Start 2014-10
  48. A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric CancerCompletedNCT01839500Study siteStart 2013-04

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatoblastoma

肝母细胞瘤

Led no English-language PubMed papers on hepatoblastoma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

8 hospitals in Guangzhou for hepatoblastoma88 hospitals in China for hepatoblastoma

No open trial on hepatoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. Downregulation of hepatic lipase is associated with decreased CD133 expression and clone formation in HepG2 cells.2018International journal of molecular medicine

Run the PubMed searchClinicalTrials.gov

Cancer

Retinoblastoma

视网膜母细胞瘤

Led no English-language PubMed papers on retinoblastoma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

8 hospitals in Guangzhou for retinoblastoma196 hospitals in China for retinoblastoma

No open trial on retinoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 6 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.3%.

Papers led
6
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 3320222023: 1120232024: 1120242025: 112025

33 hospitals in Guangzhou for osteosarcoma742 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRadiology / nuclear medicineNeurosurgery

Over half of these papers are lab or animal studies.

Papers it led6
  1. Natural product Eriocalyxin B exerts anti-tumor effects by downregulating TCEA3 expression and sensitizes immune checkpoint blockade therapy in osteosarcoma.2025Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas
  2. Imaging diagnosis and differential diagnosis of extraskeletal osteosarcoma.2024BMC cancer
  3. A rare case of long venous tumor thrombi from the right femoral vein to the right ventricle visualized by [18F]-FDG PET/CT in a patient with chondrogenic osteosarcoma.2023European journal of nuclear medicine and molecular imaging
  4. Tribbles Pseudokinase 2 Promotes the Proliferation, Migration, and Invasion of Osteosarcoma through Modulating AP4/p21 Pathway.2022Annals of clinical and laboratory science
  5. Individualized combination therapies based on whole-exome sequencing displayed significant clinical benefits in a glioblastoma patient with secondary osteosarcoma: case report and genetic characterization.2022BMC neurology
  6. Identification and validation of miR-509-5p as a prognosticator for favorable survival in osteosarcoma.2022Medicine
Earlier papers (2016–2020)9
  1. Head and neck osteosarcoma: CT and MR imaging features.2020Dento maxillo facial radiology
  2. CT and MRI features of calvarium and skull base osteosarcoma (CSBO).2020The British journal of radiology
  3. lncRNA SNHG1 negatively regulates miRNA‑101‑3p to enhance the expression of ROCK1 and promote cell proliferation, migration and invasion in osteosarcoma.2019International journal of molecular medicine
  4. Dysregulated circRNA_100876 suppresses proliferation of osteosarcoma cancer cells by targeting microRNA-136.2019Journal of cellular biochemistry
  5. The extremity localized classic osteosarcomas have better survival than the axial non-classics.2018World journal of surgical oncology
  6. miR-451 inhibits cell growth, migration and angiogenesis in human osteosarcoma via down-regulating IL 6R.2017Biochemical and biophysical research communications
  7. MiR-451 suppresses proliferation, migration and promotes apoptosis of the human osteosarcoma by targeting macrophage migration inhibitory factor.2017Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  8. Overexpression of miR-664 is associated with enhanced osteosarcoma cell migration and invasion ability via targeting SOX7.2017Clinical and experimental medicine
  9. Knockdown of UBE2T Inhibits Osteosarcoma Cell Proliferation, Migration, and Invasion by Suppressing the PI3K/Akt Signaling Pathway.2016Oncology research

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led 2 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 0.4%.

Papers led
2
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

13 hospitals in Guangzhou for gastrointestinal stromal tumour261 hospitals in China for gastrointestinal stromal tumour

No open trial on gastrointestinal stromal tumour lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersGastroenterology / hepatology
Papers it led2
  1. Comparison between cap-aspiration lumpectomy versus endoscopic submucosal dissection for the treatment of small gastric submucosal tumors: a prospective randomized controlled trial.2025Surgical endoscopy
  2. Long-term outcomes of endoscopic therapy versus surgical resection for 2-5 cm gastric gastrointestinal stromal tumors: A population-based comparative study.2024European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
Earlier papers (2016–2020)14
  1. Laparoscopic resection is better than endoscopic dissection for gastric gastrointestinal stromal tumor between 2 and 5 cm in size: a case-matched study in a gastrointestinal center.2020Surgical endoscopy
  2. Developed and validated a prognostic nomogram for recurrence-free survival after complete surgical resection of local primary gastrointestinal stromal tumors based on deep learning.2019EBioMedicine
  3. A new nomogram for recurrence-free survival prediction of gastrointestinal stromal tumors: Comparison with current risk classification methods.2019European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  4. The roles of CT and EUS in the preoperative evaluation of gastric gastrointestinal stromal tumors larger than 2 cm.2019European radiology
  5. Radiomics nomogram for predicting the malignant potential of gastrointestinal stromal tumours preoperatively.2019European radiology
  6. Performance of risk stratification systems for gastrointestinal stromal tumors: A multicenter study.2019World journal of gastroenterology
  7. Effectiveness and safety of endoscopic resection for gastric GISTs: a systematic review.2018Minimally invasive therapy & allied technologies : MITAT : official journal of the Society for Minimally Invasive Therapy
  8. Comparison of endoscopic submucosal tunneling dissection and thoracoscopic enucleation for the treatment of esophageal submucosal tumors.2017Gastrointestinal endoscopy
  9. Meta-analysis of laparoscopic vs. open resection of gastric gastrointestinal stromal tumors.2017PloS one
  10. Safety analysis of laparoscopic endoscopic cooperative surgery versus endoscopic submucosal dissection for selected gastric gastrointestinal stromal tumors: a propensity score-matched study.2017Surgical endoscopy
  11. Retrospective study of laparoscopic versus open gastric resection for gastric gastrointestinal stromal tumors based on the propensity score matching method.2017Surgical endoscopy
  12. Laparoscopic management of gastric gastrointestinal stromal tumors: A retrospective 10-year single-center experience.2017World journal of gastroenterology
  13. [Comparison of modified NIH and AFIP risk-stratification criteria for gastrointestinal stromal tumors: A multicenter retrospective study].2017Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  14. Endoscopic band ligation versus endoscopic submucosal dissection and laparoscopic resection for small gastric stromal tumors.2016Surgical endoscopy
All its trials on ClinicalTrials.gov, any status3
  1. Comparison of Endoscopic and Laparoscopic Resection for Small Gastric Gastrointestinal Stromal TumorStatus unknownNCT03471273Lead sponsorN/AStart 2017-09
  2. ESTD vs. VATS for Upper Gastrointestinal Submucosal TumorsStatus unknownNCT01768104Lead sponsorN/AStart 2011-12
  3. Second-line Pharmacotherapy Patterns and Outcomes of Advanced Gastrointestinal Stromal Tumor: A Real-world StudyStatus unknownNCT05440357Study siteStart 2022-07

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led 2 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.2%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 1120242025: 002025

23 hospitals in Guangzhou for neuroblastoma352 hospitals in China for neuroblastoma

No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 3 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.2%.

Papers led
3
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
5
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 0020242025: 112025

14 hospitals in Guangzhou for multiple myeloma178 hospitals in China for multiple myeloma

Open trials with this hospital 5

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
    Phase
    Phase 3
    Started
    2026-06
    Registry
    NCT07555938

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesGuangzhou, Hangzhou, Jinan, Kunming, Nanjing, Qingdao, Shanghai, Suzhou, Tianjin, Wenzhou, Wuhan

  2. Recruiting
    A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell Tumors
    Phase
    Phase 1
    Started
    2025-12
    Registry
    NCT07179679

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesChengde, Chongqing, Guangzhou, Nanchang, Nanchong, Nanjing, Shanghai, Suzhou, Xi'an

  3. Recruiting
    A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
    Phase
    Phase 3
    Started
    2022-10
    Registry
    NCT05552222

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shenzhen, Tianjin, Wenzhou, Wuhan, Xi'an, Xiamen, Zhengzhou

  4. Recruiting
    A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
    Phase
    Phase 3
    Started
    2022-11
    Registry
    NCT05623020

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Changchun, Fuzhou, Guangzhou, Hangzhou, Nanjing, Shanghai, Suzhou, Tianjin, Wenzhou, Wuhan

  5. Recruiting
    A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
    Phase
    Phase 3
    Started
    2021-10
    Registry
    NCT05020236

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBeijing, Changchun, Chongqing, Fuzhou, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Shenzhen, Shijiazhuang, Tianjin, Wenzhou, Wuhan, Xuzhou, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesDiagnosis, MRD & riskStem cell transplant
Papers it led3
  1. Low peripheral blood B lymphocyte count predicts poor outcome in patients with multiple myeloma.2025Immunobiology
  2. Stem cell mobilization in multiple myeloma: challenges, strategies, and current developments.2023Annals of hematologyFree full text
  3. CD43 is an adverse prognostic factor in newly diagnosed multiple myeloma.2022Leukemia & lymphoma
Chinese-language papers (not in the count)1
  1. [Autologous stem cell transplantation improves outcomes of patients with multiple myeloma receiving proteasome inhibitors and lenalidomide treatment].2021Nan fang yi ke da xue xue bao = Journal of Southern Medical UniversityFree full text
All its trials on ClinicalTrials.gov, any status21
  1. Mel vs BUCY+VP-16 Conditioning Regimen for MM Undergoing Auto-HSCTStatus unknownNCT03385096Lead sponsorPhase 2/Phase 3Start 2018-01
  2. Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple MyelomaRecruitingNCT07555938Study sitePhase 3Start 2026-06
  3. A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell TumorsRecruitingNCT07179679Study sitePhase 1Start 2025-12
  4. A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for TransplantRecruitingNCT05623020Study sitePhase 3Start 2022-11
  5. A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple MyelomaRecruitingNCT05552222Study sitePhase 3Start 2022-10
  6. A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other TreatmentsRecruitingNCT05020236Study sitePhase 3Start 2021-10
  7. A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and LenalidomideActive, not recruitingNCT06208150Study sitePhase 3Start 2024-01
  8. A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)Active, not recruitingNCT06464991Study sitePhase 3Start 2024-03
  9. Selinexor Plus VRd in High Risk Newly Diagnosed Multiple MyelomaStatus unknownNCT05422027Study sitePhase 1/Phase 2Start 2022-07
  10. A Study of DaratumumabActive, not recruitingNCT05438043Study sitePhase 3Start 2022-12
  11. A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.CompletedNCT05228470Study sitePhase 2Start 2021-12
  12. A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)CompletedNCT04939142Study sitePhase 3Start 2021-07
  13. A Study of Subcutaneous Delivery of JNJ-54767414 in Chinese Participants With Multiple MyelomaCompletedNCT04121260Study sitePhase 1Start 2019-12
  14. TJ202 Combined With Dexamethasone in Subjects With Relapsed or Refractory Multiple MyelomaCompletedNCT03860038Study sitePhase 2Start 2019-01
  15. A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed Refractory Multiple MyelomaCompletedNCT03944057Study sitePhase 2Start 2019-09
  16. TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple MyelomaCompletedNCT03952091Study sitePhase 3Start 2019-03
  17. A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)CompletedNCT03217812Study sitePhase 3Start 2017-11
  18. A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple MyelomaCompletedNCT03234972Study sitePhase 3Start 2017-11
  19. Observational Registry Study of Chinese Patients Treated With Revlimid (Lenalidomide)TerminatedNCT01947309Study siteStart 2013-11
  20. Open-label Extended Access Program on Lenalidomide Plus Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma Who Participated in CC-5013-MM021 for at Least 1 YearCompletedNCT02348528Study sitePhase 2Start 2012-09
  21. Study of Lenalidomide and Low-Dose Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple MyelomaCompletedNCT01593410Study sitePhase 2Start 2010-08

Run the PubMed searchClinicalTrials.gov

Blood disorders

B-cell acute lymphoblastic leukaemia

B 细胞急性淋巴细胞白血病

Led 8 of the 225 English-language PubMed papers on B-cell acute lymphoblastic leukaemia with an author in mainland China, 2021–2025: 3.6%.

Papers led
8
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
5
led by another institution
Papers led per year
2021: 0020212022: 2220222023: 0020232024: 4420242025: 222025

8 hospitals in Guangzhou for B-cell acute lymphoblastic leukaemia90 hospitals in China for B-cell acute lymphoblastic leukaemia

Open trials with this hospital 5

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol
    Phase
    Phase 2/Phase 3
    Started
    2025-01
    Registry
    NCT06764238

    Age 1 month to 18 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 24 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hefei, Jinan, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenzhen, Suzhou, Tianjin, Wuhan, Xi'an

  2. Recruiting
    Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol
    Phase
    Phase 2/Phase 3
    Started
    2025-03
    Registry
    NCT06882057

    Age 1 year to 18 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 23 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hefei, Jinan, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Suzhou, Tianjin, Wuhan, Xi'an

  3. Recruiting
    Newly-diagnosed Pediatric Ph-positive B-ALL Protocol
    Phase
    Phase 3
    Started
    2025-03
    Registry
    NCT07152041

    Age 1 month to 18 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 20 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Jinan, Nanchang, Nanjing, Qingdao, Shanghai, Shenzhen, Suzhou, Tianjin, Wuhan

  4. Recruiting
    A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)
    Phase
    Phase 1/Phase 2
    Started
    2023-02
    Registry
    NCT05667506

    Age 3 years to 18 years (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesChongqing, Guangzhou, Hefei, Nanchang, Nanjing, Tianjin, Wuhan, Xuzhou

  5. Recruiting
    A Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002)
    Phase
    Phase 1/Phase 2
    Started
    2022-11
    Registry
    NCT05579132

    Age 2 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesChengdu, Chongqing, Guangzhou, Hangzhou, Tianjin, Wuhan, Xuzhou, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesPhiladelphia chromosome & geneticsChildrenMRD & relapse
Departments in papersPediatrics
Papers it led8
  1. Integrating bulk RNA-seq and scRNA-seq data to explore diverse cell death patterns and develop a programmed cell death-related relapse prediction model in pediatric B-ALL.2025Scientific reportsFree full text
  2. Refining Risk Stratification for B-cell Precursor Adult Acute Lymphoblastic Leukemia Treated With a Pediatric-inspired Regimen by Combining IKZF1 Deletion and Minimal Residual Disease.2025Transplantation and cellular therapy
  3. A meta-analysis of the prognostic significance of CDKN deletions in acute lymphoblastic leukaemia.2024Annals of medicineFree full text
  4. STAT5 phosphorylation plus minimal residual disease defines a novel risk classification in adult B-cell acute lymphoblastic leukaemia.2024British journal of haematology
  5. PASS-ALL study of paediatric-inspired versus adult chemotherapy regimens on survival of high-risk Philadelphia-negative B-cell acute lymphoblastic leukaemia with allogeneic haematopoietic stem cell transplantation.2024British journal of haematology
  6. Dynamic evolution of bone marrow adipocyte in B cell acute lymphoblastic leukemia: insights from diagnosis to post-chemotherapy.2024Cancer biology & therapy
  7. Allogeneic hematopoietic stem cell transplantation overcome the poor prognosis of patients with IKZF1plus CD20-a very high-risk subtype in B-cell acute lymphoblastic leukemia.2022Bone marrow transplantation
  8. Efficacy and safety of blinatumomab in Chinese adults with Ph-negative relapsed/refractory B-cell precursor acute lymphoblastic leukemia: A multicenter open-label single-arm China registrational study.2022Hematology (Amsterdam, Netherlands)
Chinese-language papers (not in the count)1
  1. [Prognostic significance of IKZF1 gene deletions in patients with B-cell acute lymphoblastic leukemia].2022Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
All its trials on ClinicalTrials.gov, any status9
  1. Induced-T Cell Like NK Cells for B Cell MalignanciesStatus unknownNCT04747093Lead sponsorPhase 1/Phase 2Start 2021-01
  2. Precision Diagnosis Directing HDACi and TKI Target Therapy for Adult Ph-like ALLStatus unknownNCT03564470Lead sponsorPhase 2/Phase 3Start 2016-02
  3. Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL ProtocolRecruitingNCT06764238Study sitePhase 2/Phase 3Start 2025-01
  4. Newly-diagnosed Pediatric Ph-positive B-ALL ProtocolRecruitingNCT07152041Study sitePhase 3Start 2025-03
  5. Newly-diagnosed Low Risk Pediatric B-cell ALL ProtocolRecruitingNCT06882057Study sitePhase 2/Phase 3Start 2025-03
  6. A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)RecruitingNCT05667506Study sitePhase 1/Phase 2Start 2023-02
  7. A Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002)RecruitingNCT05579132Study sitePhase 1/Phase 2Start 2022-11
  8. A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALLActive, not recruitingNCT04521231Study sitePhase 1/Phase 2Start 2021-01
  9. Efficacy and Safety of the BiTE Antibody Blinatumomab in Chinese Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)CompletedNCT03476239Study sitePhase 3Start 2017-10

Run the PubMed searchClinicalTrials.gov

Blood disorders

Beta thalassaemia

β 地中海贫血

Led 21 of the 312 English-language PubMed papers on beta thalassaemia with an author in mainland China, 2021–2025: 6.7%.

Papers led
21
2021–2025
Trials led
5
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 1120212022: 2220222023: 3320232024: 7720242025: 882025

23 hospitals in Guangzhou for beta thalassaemia157 hospitals in China for beta thalassaemia

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia
    Phase
    Phase 2
    Started
    2019-11
    Registry
    NCT04143724

    Age 6 years to 17 years (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesChengdu, Guangzhou, Nanning, Shenzhen

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersPediatricsPathology / laboratory medicine
Papers it led21
  1. Haplotype-Resolved Genotyping and Association Analysis of 1,020 β-Thalassemia Patients by Targeted Long-Read Sequencing.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)
  2. Rapid detection of genetic modifiers of β-thalassemia based on MALDI-TOF MS.2025Annals of hematology
  3. Mutations in AMBRA1 aggravate β-thalassemia by impairing autophagy-mediated clearance of free α-globin.2025Blood
  4. A common TBP-binding site mutation elevates fetal hemoglobin levels by competitive globin switching change in β-thalassemia.2025Blood advances
  5. Whole-genome Sequencing Association Analysis of Quantitative Platelet Traits in A Large Cohort of β-thalassemia.2025Genomics, proteomics & bioinformatics
  6. A Chinese pediatric patient with thalassemia traits and compound heterozygous mutations in the PIEZO1 gene suspected of having dehydrated hereditary stomatocytosis.2025Hematology (Amsterdam, Netherlands)
  7. Identification of a Patient with Transfusion-Dependent β-Thalassemia Caused by Compound Heterozygous Mutations of HBB: C.84_85insC and Common Linked Intronic Variants in HBB.2025Hemoglobin
  8. Activation of γ-globin expression by a common variant disrupting IKAROS-binding motif in β-thalassemia.2025Journal of genetics and genomics = Yi chuan xue bao
  9. Identification and characterization of CHD4-associated eRNA as a novel modulator of fetal hemoglobin levels in β-thalassemia.2024Biochemical and biophysical research communications
  10. Characterization of a novel 8.2 kb deletion causing beta-thalassemia.2024Clinical biochemistry
  11. Activation of γ-globin expression by LncRNA-mediated ERF promoter hypermethylation in β-thalassemia.2024Clinical epigenetics
  12. SUPT5H mutations associated with elevation of Hb A2 level: Identification of two novel variants and literature review.2024Gene
  13. An unusual case of thalassemia intermedia with inheritable complex repeats detected by single-molecule optical mapping.2024Haematologica
  14. Prevalence of thalassaemia among childbearing-age Li and Han populations in Hainan Province.2024Hematology (Amsterdam, Netherlands)
  15. Safety and efficacy of peripheral blood stem cells collection in healthy children and pediatric patients with thalassemia major weighing 20 kg or less.2024Journal of clinical apheresis
  16. The Effect of Iron Overload on the Mobilization of Peripheral Blood Hematopoietic Stem Cells in Pediatric Patients with Thalassemia Major.2023Acta haematologica
  17. A novel gain-of-function PIP4K2A mutation elevates the expression of β-globin and aggravates the severity of α-thalassemia.2023British journal of haematology
  18. Target-allele-specific probe single-base extension (TASP-SBE): a novel MALDI-TOF-MS strategy for multi-variants analysis and its application in simultaneous detection of α-/β-thalassemia mutations.2023Human geneticsRCT
  19. Iron parameters in pregnant women with beta-thalassaemia minor combined with iron deficiency anaemia compared to pregnant women with iron deficiency anaemia alone demonstrate the safety of iron supplementation in beta-thalassaemia minor dur2022British journal of haematology
  20. MALDI-TOF-MS for Rapid Screening and Typing of β-Globin Variant and β-Thalassemia through Direct Measurements of Intact Globin Chains.2022Clinical chemistry
  21. TEA domain transcription factor 4 modulates repression of fetal haemoglobin by direct binding to the γ-globin gene promoters.2021British journal of haematology
Earlier papers (2016–2020)6
  1. Long-term results of the NF-08-TM protocol in stem cell transplant for patients with thalassemia major: A multi-center large-sample study.2020American journal of hematology
  2. Oridonin enhances γ‑globin expression in erythroid precursors from patients with β‑thalassemia via activation of p38 MAPK signaling.2020Molecular medicine reports
  3. Related and unrelated donor transplantation for β-thalassemia major: results of an international survey.2019Blood advances
  4. Non-invasive prenatal testing for fetal inheritance of maternal β-thalassaemia mutations using targeted sequencing and relative mutation dosage: a feasibility study.2018BJOG : an international journal of obstetrics and gynaecology
  5. Genetic diagnosis of polycystic kidney disease, Alport syndrome, and thalassemia minor in a large Chinese family.2017Clinical science (London, England : 1979)
  6. [Nosocomial septicemia in the early stage after stem cell transplantation in children with major β-thalassemia].2016Nan fang yi ke da xue xue bao = Journal of Southern Medical University
All its trials on ClinicalTrials.gov, any status8
  1. Evaluation of Heart Status in Patients of Beta Thalassemia Using EchocardiogramStatus unknownNCT04929574Lead sponsorStart 2021-07
  2. Association of Hb F Level With Clinical Severity of Beta ThalassemiaStatus unknownNCT04917978Lead sponsorStart 2019-12
  3. Genetic Variants Affecting the Clinical Severity of Beta ThalassemiaStatus unknownNCT04918056Lead sponsorStart 2017-01
  4. Gene Therapy for Beta-Thalassemia Major Using Autologous Hematopoietic Stem Cell Genetically ModifiedStatus unknownNCT03276455Lead sponsorPhase 1/Phase 2Start 2017-09
  5. Unrelated Umbilical Cord Blood Following HLA-haploidentical Hematopoietic Stem Cell Transplantation in Patients With β-thalassemia MajorStatus unknownNCT02126046Lead sponsorN/AStart 2012-09
  6. Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-ThalassemiaRecruitingNCT04143724Study sitePhase 2Start 2019-11
  7. Safety and Efficacy Evaluation of BRL-101 in Subjects With Transfusion-Dependent β-ThalassemiaActive, not recruitingNCT05577312Study sitePhase 1/Phase 2Start 2022-11
  8. A Safety and Efficacy Study Evaluating ET-01 in Subjects with Transfusion Dependent Β-ThalassaemiaTerminatedNCT04925206Study sitePhase 1Start 2021-08

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophilia A

血友病 A

Led 9 of the 272 English-language PubMed papers on haemophilia A with an author in mainland China, 2021–2025: 3.3%.

Papers led
9
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
3
led by another institution
Papers led per year
2021: 3320212022: 1120222023: 1120232024: 0020242025: 222025

8 hospitals in Guangzhou for haemophilia A160 hospitals in China for haemophilia A

Open trials with this hospital 3

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A
    Phase
    Phase 3
    Started
    2026-04
    Registry
    NCT07416604

    Age 12 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Tianjin

  2. Recruiting
    To Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia A
    Phase
    Phase 3
    Started
    2025-03
    Registry
    NCT06833983

    Age 18 years to 65 years; men only (registered criteria)

    Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesBeijing, Changsha, Guangzhou, Hefei, Jinan, Kunming, Lanzhou, Nanchang, Nanjing, Tangshan, Tianjin, Wuhan, Zhengzhou

  3. Recruiting
    Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
    Phase
    Phase 3
    Started
    2021-11
    Registry
    NCT05145127

    Age 1 year to 74 years; men only (registered criteria)

    Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesBeijing, Guangzhou, Guiyang, Nanchang, Tianjin, Wuhan

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersPediatricsPathology / laboratory medicine
Papers it led9
  1. Coagulation Factor Consumption and Medium- to Long-Term Outcomes of Achilles Tendon Lengthening With and Without External Fixation in Haemophilia.2026Haemophilia : the official journal of the World Federation of Hemophilia
  2. Treatment of fracture in haemophilia: a retrospective study.2026International orthopaedics
  3. Efficacy and Safety of Recombinant Factor VIII in Previously Untreated and Previously Treated Children with Hemophilia A: A Systematic Review.2025Advances in therapy
  4. Application of capillary gel electrophoresis in detection of Factor VIII gene intron 22 inversion of hemophilia A.2025Journal of hematopathology
  5. Relationship between serum cartilage turnover biomarkers and haemophilic arthropathy severity in adult patients with severe haemophilia A in China.2023Haemophilia : the official journal of the World Federation of Hemophilia
  6. Value of Contrast-enhanced Ultrasound in Evaluating Synovitis and Predicting Recurrent Joint Bleeding of Hemophilia.2022Current medical science
  7. Surgical treatment for patients with hemophilic pseudotumor-related femoral fracture: a retrospective study.2021Journal of orthopaedic surgery and research
  8. Factor VIII replacement prophylaxis in patients with hemophilia A transitioning to adults: a systematic literature review.2021Orphanet journal of rare diseases
  9. The spectrum of FVIII gene variants detected by next generation sequencing in 236 Chinese non-inversion hemophilia A pedigrees.2021Thrombosis research
Chinese-language papers (not in the count)1
  1. [Effect of FVIII doses on joint structure and function in adolescents with severe hemophilia A: mid-term results of a prospective cohort study].2021Nan fang yi ke da xue xue bao = Journal of Southern Medical University
Earlier papers (2016–2020)11
  1. Target capture next-generation sequencing in non-inversion haemophilia: an alternative approach.2020British journal of haematology
  2. Treatment of pelvic haemophilic pseudotumour: A retrospective study.2020Haemophilia : the official journal of the World Federation of Hemophilia
  3. Clinical characteristics and surgical treatment of haemophilic pseudotumor: A retrospective analysis of thirty-four patients.2020Haemophilia : the official journal of the World Federation of Hemophilia
  4. Intracranial Hemorrhage in Children With Inherited Bleeding Disorders: A Single Center Study in China.2019Journal of pediatric hematology/oncology
  5. [Efficacy of short-term full-dose prophylaxis in adult Chinese patients with severe hemophilia A].2018Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  6. [Prophylactic treatment with low- and intermediate-dose factor VIII in children with severe hemophilia A: comprehensive evaluation of joint outcomes and correlation analysis].2018Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  7. The demographics, treatment characteristics and quality of life of adult people with haemophilia in China - results from the HERO study.2017Haemophilia : the official journal of the World Federation of Hemophilia
  8. [Breakthrough bleeding in adult patients with severe hemophilia A receiving low- and intermediate-dose FVIII for tertiary prophylaxis: characteristics and influencing factors].2017Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  9. Efficacy of standard prophylaxis versus on-demand treatment with bayer's sucrose-formulated recombinant FVIII (rFVIII-FS) in Chinese children with severe hemophilia A.2017Pediatric hematology and oncology
  10. Haemophilic pseudotumour with fistulae formation: a retrospective report of five infected cases.2016Haemophilia : the official journal of the World Federation of Hemophilia
  11. [Modified Bethesda, modified Nijmegen and blank assays for coagulation factor VIII inhibitor detection and factors affecting the results].2016Nan fang yi ke da xue xue bao = Journal of Southern Medical University
All its trials on ClinicalTrials.gov, any status26
  1. A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia ARecruitingNCT07416604Study sitePhase 3Start 2026-04
  2. To Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia ARecruitingNCT06833983Study sitePhase 3Start 2025-03
  3. Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without InhibitorsRecruitingNCT05145127Study sitePhase 3Start 2021-11
  4. Study of Efficacy and Safety of FRSW107 in Pediatric Patients With Severe Hemophilia ANot yet recruitingNCT06136507Study sitePhase 3Start 2026-12
  5. Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) as Prophylactic Treatment.Active, not recruitingNCT07684898Study sitePhase 3Start 2026-06
  6. Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) On-Demand TreatmentActive, not recruitingNCT07663903Study sitePhase 3Start 2026-04
  7. Recombinant Single-chain Factor VIII (rVIII-SingleChain) in Chinese Participants With Hemophilia A Previously Treated With FVIII ProductsCompletedNCT06738485Study sitePhase 3Start 2025-01
  8. A Clinical Study of Recombinant Human Coagulation Factor VIII for Injection in Patients With Severe Hemophilia AActive, not recruitingNCT06297655Study sitePhase 3Start 2024-11
  9. A Study of Adynovate in Previously Treated Chinese Teenagers and Adults With Severe Hemophilia ACompletedNCT05707351Study sitePhase 3Start 2023-03
  10. A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia AActive, not recruitingNCT05685238Study sitePhase 3Start 2023-02
  11. Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion ProteinCompletedNCT06142552Study sitePhase 3Start 2023-12
  12. A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia BRecruitingNCT05611801Study sitePhase 3Start 2022-12
  13. Clinical Study of Recombinant Human Activated Coagulation Factor VII for Injection in Patients With Hemophilia With InhibitorStatus unknownNCT05487976Study sitePhase 3Start 2022-04
  14. A Research Study Looking at Mim8 in Children With Haemophilia A With or Without InhibitorsCompletedNCT05306418Study sitePhase 3Start 2022-04
  15. Efficacy and Safety of Turoctocog Alfa Pegol (N8-GP) for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia A (pathfinder10)CompletedNCT05082116Study sitePhase 3Start 2021-09
  16. Phase III Expansion Trial for Determining the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia ACompletedNCT04845399Study sitePhase 3Start 2021-04
  17. A Study to Evaluate the Pharmacokinetics,Safety and Tolerability of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for InjectionCompletedNCT04864743Study sitePhase 1Start 2021-06
  18. A Research Study Investigating Mim8 in Adults and Adolescents With Haemophilia A With or Without InhibitorsCompletedNCT05053139Study sitePhase 3Start 2021-12
  19. A Study to Evaluate the Safety and Pharmacokinetic of Recombinant Human Coagulation Factor VIII ,Fc Fusion Protein for InjectionCompletedNCT05251090Study sitePhase 1Start 2021-06
  20. Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia BCompletedNCT03938792Study sitePhase 3Start 2020-03
  21. An Open Label Study to Determine the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A.CompletedNCT04456387Study sitePhase 3Start 2020-10
  22. A Study to Evaluate the Pharmacokinetics of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for InjectionStatus unknownNCT03747653Study siteStart 2019-03
  23. Efficacy, Safety, and Pharmacokinetic Study of Prophylactic Emicizumab Versus No Prophylaxis in Hemophilia A ParticipantsCompletedNCT03315455Study sitePhase 3Start 2018-04
  24. PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Hemophilia ACompletedNCT02492984Study sitePhase 4Start 2015-04
  25. A Prospective Study to Collect High-Quality Documentation of Bleeds, Health-Related Quality of Life (HRQoL), and Safety Outcomes in Patients With Hemophilia A Treated With Standard-of-Care TreatmentCompletedNCT02476942Study siteStart 2015-05
  26. ADVATE/ ADYNOVI Hemophilia A Outcome Database (AHEAD)CompletedNCT02078427Study siteStart 2011-06

Run the PubMed searchClinicalTrials.gov

Blood disorders

Atypical haemolytic uraemic syndrome

非典型溶血性尿毒症综合征

Led 1 of the 27 English-language PubMed papers on atypical haemolytic uraemic syndrome with an author in mainland China, 2021–2025: 3.7%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

1 hospital in Guangzhou for atypical haemolytic uraemic syndrome31 hospitals in China for atypical haemolytic uraemic syndrome

No open trial on atypical haemolytic uraemic syndrome lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPediatrics
Papers it led1
  1. Cyclosporine A relieved proteinuria and hypoproteinemia in DGKE nephropathy.2021Clinica chimica acta; international journal of clinical chemistry

Run the PubMed searchClinicalTrials.gov

Other diseases

Neuromyelitis optica spectrum disorder

视神经脊髓炎谱系疾病

Led 3 of the 485 English-language PubMed papers on neuromyelitis optica spectrum disorder with an author in mainland China, 2021–2025: 0.6%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 2220222023: 0020232024: 0020242025: 002025

9 hospitals in Guangzhou for neuromyelitis optica spectrum disorder67 hospitals in China for neuromyelitis optica spectrum disorder

No open trial on neuromyelitis optica spectrum disorder lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesAntibodies & diagnosis
Departments in papersNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Myasthenia gravis

重症肌无力

Led 1 of the 499 English-language PubMed papers on myasthenia gravis with an author in mainland China, 2021–2025: 0.2%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

8 hospitals in Guangzhou for myasthenia gravis93 hospitals in China for myasthenia gravis

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.
    Phase
    Phase 2/Phase 3
    Started
    2024-07
    Registry
    NCT06447597

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Jinan, Nanchang, Shanghai, Wuhan, Xi'an

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesThymus & thymectomy

Run the PubMed searchClinicalTrials.gov

Other diseases

Moyamoya disease

烟雾病

Led 6 of the 356 English-language PubMed papers on moyamoya disease with an author in mainland China, 2021–2025: 1.7%.

Papers led
6
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 2220232024: 0020242025: 112025

3 hospitals in Guangzhou for moyamoya disease47 hospitals in China for moyamoya disease

No open trial on moyamoya disease lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesRevascularisation surgeryImaging & blood flowGenetics
Departments in papersNeurosurgeryRadiology / nuclear medicine
Papers it led6
  1. Multiple arachnoid membrane opening to promote angiogenesis in adult patients with moyamoya disease after combined bypass surgery: a multicenter randomized controlled clinical trial.2026Journal of neurosurgeryRCT
  2. miR-6760-5p suppresses neoangiogenesis by targeting Yes-associated protein 1 in patients with moyamoya disease undergoing indirect revascularization.2025Gene
  3. Is STA really a low-flow graft? A quantitative ultrasonographic study of the flow of STA for cerebral revascularization in MMD patients.2023CNS neuroscience & therapeuticsFree full text
  4. Association of Cerebral Hemodynamics and Cognitive Function in Adult Patients with Moyamoya Disease: A Three-Dimensional Pseudo-Continuous Arterial Spin Labeling Study.2023World neurosurgery
  5. A Preliminary Report of One-Session Treatment with Cranioplasty and Superficial Temporal Artery-Middle Cerebral Artery Bypass for Hemorrhagic Moyamoya Disease Patients with Skull Defect.2022World neurosurgery
  6. Use of a panel of four microRNAs in CSF as a predicted biomarker for postoperative neoangiogenesis in moyamoya disease.2021CNS neuroscience & therapeuticsFree full text
Chinese-language papers (not in the count)1
  1. [Three-dimensional pseudo-continuous arterial spin labeling for evaluation of cerebral hemodynamic changes after revascularization in adult patients with moyamoya disease].2023Nan fang yi ke da xue xue bao = Journal of Southern Medical UniversityFree full text
More papers found outside PubMed (not counted)3
  1. miR-486-3p ameliorates aging-related impaired angiogenesis in adult moyamoya disease by targeting Forkhead Box O42025bioRxiv (Cold Spring Harbor Laboratory)preprint
  2. miR-6760-5p suppresses neoangiogenesis by targeting Yes-associated protein 1 in patients with moyamoya disease undergoing indirect revascularization2024Research Squarepreprint
  3. Moyamoya Disease Manifesting as Paroxysmal Kinesigenic Dystonia: A Case Report and Literature Review2023Research Squarepreprint

Run the PubMed searchClinicalTrials.gov

Other diseases

Anti-NMDA receptor encephalitis

抗 NMDA 受体脑炎

Led 7 of the 264 English-language PubMed papers on anti-NMDA receptor encephalitis with an author in mainland China, 2021–2025: 2.6%.

Papers led
7
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 4420212022: 0020222023: 1120232024: 1120242025: 112025

12 hospitals in Guangzhou for anti-NMDA receptor encephalitis126 hospitals in China for anti-NMDA receptor encephalitis

No open trial on anti-NMDA receptor encephalitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology

Over half of these papers are lab or animal studies.

Papers it led7
  1. Chaihu Guizhi Decoction prevents cognitive, memory impairments and sensorimotor gating deficit induced by N-methyl-d-aspartate receptor antibody in mice.2025Journal of ethnopharmacology
  2. Exploring the neuroprotective role of artesunate in mouse models of anti-NMDAR encephalitis: insights from molecular mechanisms and transmission electron microscopy.2024Cell communication and signaling : CCS
  3. Multi-proteomic Analysis Revealed Distinct Protein Profiles in Cerebrospinal Fluid of Patients Between Anti-NMDAR Encephalitis NORSE and Cryptogenic NORSE.2023Molecular neurobiology
  4. Clinical analysis of five case reports of ovarian teratoma withanti-N-methyl-D-aspartate receptor encephalitis.2021Annals of palliative medicine
  5. High Level of Soluble CD146 In Cerebrospinal Fluid Might be a Biomarker of Severity of Anti-N-Methyl-D-Aspartate Receptor Encephalitis.2021Frontiers in immunology
  6. Paroxysmal Sympathetic Hyperactivity in Severe Anti-N-Methyl-d-Aspartate Receptor Encephalitis: A Single Center Retrospective Observational Study.2021Frontiers in immunology
  7. Anti-NMDAR encephalitis induced in mice by active immunization with a peptide from the amino-terminal domain of the GluN1 subunit.2021Journal of neuroinflammation
Earlier papers (2016–2020)10
  1. A refractory anti-NMDA receptor encephalitis successfully treated by bilateral salpingo-oophorectomy and intrathecal injection of methotrexate and dexamethasone: a case report.2020The Journal of international medical research
  2. Clinical significance of soluble adhesion molecules in anti-NMDAR encephalitis patients.2019Annals of clinical and translational neurology
  3. Cerebrospinal fluid light and heavy neurofilament level increased in anti-N-methyl-d-aspartate receptor encephalitis.2019Brain and behavior
  4. Higher CSF Levels of NLRP3 Inflammasome Is Associated With Poor Prognosis of Anti-N-methyl-D-Aspartate Receptor Encephalitis.2019Frontiers in immunology
  5. Cell-Free Mitochondrial DNA in the CSF: A Potential Prognostic Biomarker of Anti-NMDAR Encephalitis.2019Frontiers in immunology
  6. The HMGB1 is increased in CSF of patients with an Anti-NMDAR encephalitis.2018Acta neurologica Scandinavica
  7. Elevated neuron-specific enolase and S100 calcium-binding protein B concentrations in cerebrospinal fluid of patients with anti-N-methyl-d-aspartate receptor encephalitis.2018Clinica chimica acta; international journal of clinical chemistry
  8. Cerebrospinal fluid pentraxin 3 and CD40 ligand in anti-N-menthyl-d-aspartate receptor encephalitis.2018Journal of neuroimmunology
  9. Anti-N-methyl-D-aspartate receptor encephalitis associated with intracranial Angiostrongylus cantonensis infection: a case report.2017Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  10. Heterotopic ossification following anti-NMDA receptor encephalitis: a case report.2016BMC neurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led 5 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.5%.

Papers led
5
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 2220222023: 1120232024: 1120242025: 112025

20 hospitals in Guangzhou for idiopathic pulmonary fibrosis333 hospitals in China for idiopathic pulmonary fibrosis

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
    Phase
    Phase 3
    Started
    2026-09
    Registry
    NCT07687459

    Age 40 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 45 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Hohhot, Jinan, Kunming, Nanchang, Nanjing, Nanning, Nanyang, Ningbo, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Wenzhou, Wuhan, Xi'an, Xiamen, Xuzhou, Yichang, Yuncheng, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers

Over half of these papers are lab or animal studies.

Papers it led5
  1. Bioinformatics-based identification of mirdametinib as a potential therapeutic target for idiopathic pulmonary fibrosis associated with endoplasmic reticulum stress.2025Naunyn-Schmiedeberg's archives of pharmacology
  2. Tetrandrine alleviates pulmonary fibrosis by inhibiting alveolar epithelial cell senescence through PINK1/Parkin-mediated mitophagy.2024European journal of pharmacology
  3. RNF130 protects against pulmonary fibrosis through suppressing aerobic glycolysis by mediating c-myc ubiquitination.2023International immunopharmacology
  4. Extracellular HSP90α promotes cellular senescence by modulating TGF-β signaling in pulmonary fibrosis.2022FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  5. SIRT1 prevents cigarette smoking-induced lung fibroblasts activation by regulating mitochondrial oxidative stress and lipid metabolism.2022Journal of translational medicine
All its trials on ClinicalTrials.gov, any status5
  1. Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)RecruitingNCT07687459Study sitePhase 3Start 2026-09
  2. Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary FibrosisTerminatedNCT06097260Study sitePhase 2Start 2023-11
  3. Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT05938920Study sitePhase 2Start 2023-06
  4. A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary FibrosisTerminatedNCT04552899Study sitePhase 3Start 2021-03
  5. Zephyrus I: Evaluation of Efficacy and Safety of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)TerminatedNCT03955146Study sitePhase 3Start 2019-06

Run the PubMed searchClinicalTrials.gov

Other diseases

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症

Led 6 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 0.8%.

Papers led
6
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 0020222023: 1120232024: 2220242025: 112025

13 hospitals in Guangzhou for amyotrophic lateral sclerosis194 hospitals in China for amyotrophic lateral sclerosis

No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Spinal muscular atrophy

脊髓性肌萎缩症

Led 1 of the 55 English-language PubMed papers on spinal muscular atrophy with an author in mainland China, 2021–2025: 1.8%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

2 hospitals in Guangzhou for spinal muscular atrophy51 hospitals in China for spinal muscular atrophy

No open trial on spinal muscular atrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Fabry disease

法布雷病

Led 2 of the 73 English-language PubMed papers on Fabry disease with an author in mainland China, 2021–2025: 2.7%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

3 hospitals in Guangzhou for Fabry disease85 hospitals in China for Fabry disease

No open trial on Fabry disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPediatrics

Run the PubMed searchClinicalTrials.gov

Other diseases

Duchenne muscular dystrophy

杜氏肌营养不良

Led no English-language PubMed papers on Duchenne muscular dystrophy in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

7 hospitals in Guangzhou for Duchenne muscular dystrophy116 hospitals in China for Duchenne muscular dystrophy

No open trial on Duchenne muscular dystrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Alport syndrome

Alport 综合征

Led no English-language PubMed papers on Alport syndrome in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

5 hospitals in Guangzhou for Alport syndrome60 hospitals in China for Alport syndrome

No open trial on Alport syndrome lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led 5 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.7%.

Papers led
5
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 2220232024: 0020242025: 112025

20 hospitals in Guangzhou for IgA nephropathy346 hospitals in China for IgA nephropathy

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Efficacy and Safety of Nefecon on Prevention of Relapse of IgA Nephropathy
    Phase
    Phase 4
    Started
    2026-06
    Registry
    NCT07604311

    Age 18 years to 75 years (registered criteria)

    Led by Nanfang HospitalGuangzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersGastroenterology / hepatologyNephrology
Papers it led5
  1. Association of urinary LIF levels with disease prognosis and treatment response to methylprednisolone in IgA nephropathy.2025Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  2. Immunosuppression versus Supportive Care on Kidney Outcomes in IgA Nephropathy in the Real-World Setting.2023Clinical journal of the American Society of Nephrology : CJASN
  3. Effectiveness of Mycophenolate Mofetil Among Patients With Progressive IgA Nephropathy: A Randomized Clinical Trial.2023JAMA network openRCT
  4. Orange-derived and dexamethasone-encapsulated extracellular vesicles reduced proteinuria and alleviated pathological lesions in IgA nephropathy by targeting intestinal lymphocytes.2022Frontiers in immunology
  5. Intensity of Macrophage Infiltration in Glomeruli Predicts Response to Immunosuppressive Therapy in Patients with IgA Nephropathy.2021Journal of the American Society of Nephrology : JASN
Chinese-language papers (not in the count)1
  1. [The comorbidity mechanism of celiac disease and immunoglobulin A nephropathy].2025Zhonghua nei ke za zhi
Earlier papers (2016–2020)2
  1. Kidney Biopsies in Elderly Chinese Patients: A Nationwide Survey.2020American journal of kidney diseases : the official journal of the National Kidney Foundation
  2. Urinary Matrix Metalloproteinase 7 and Prediction of IgA Nephropathy Progression.2020American journal of kidney diseases : the official journal of the National Kidney Foundation
All its trials on ClinicalTrials.gov, any status4
  1. Efficacy and Safety of Nefecon on Prevention of Relapse of IgA NephropathyRecruitingNCT07604311Lead sponsorPhase 4Start 2026-06
  2. The Effects of Mycophenolate Mofetil (MMF) on Renal Outcomes in Advanced Immunoglobulin A (IgA) Nephropathy PatientsCompletedNCT01854814Lead (inferred)N/AStart 2013-07
  3. A Study to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Primary IgA Nephropathy.CompletedNCT05016323Study sitePhase 2Start 2021-09
  4. Atrasentan in Patients With IgA NephropathyActive, not recruitingNCT04573478Study sitePhase 3Start 2020-12

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary biliary cholangitis

原发性胆汁性胆管炎

Led 1 of the 300 English-language PubMed papers on primary biliary cholangitis with an author in mainland China, 2021–2025: 0.3%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

9 hospitals in Guangzhou for primary biliary cholangitis173 hospitals in China for primary biliary cholangitis

No open trial on primary biliary cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Congenital diaphragmatic hernia

先天性膈疝

Led 1 of the 60 English-language PubMed papers on congenital diaphragmatic hernia with an author in mainland China, 2021–2025: 1.7%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

4 hospitals in Guangzhou for congenital diaphragmatic hernia46 hospitals in China for congenital diaphragmatic hernia

No open trial on congenital diaphragmatic hernia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersSurgery (general/hepatobiliary/pancreatic)

Run the PubMed searchClinicalTrials.gov

Other diseases

Hirschsprung disease

先天性巨结肠

Led no English-language PubMed papers on Hirschsprung disease in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

8 hospitals in Guangzhou for Hirschsprung disease82 hospitals in China for Hirschsprung disease

No open trial on Hirschsprung disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. Laparoscopic Redo Pull-Through for Hirschsprung Disease Due to Innervation Disorders.2019Journal of laparoendoscopic & advanced surgical techniques. Part A

Run the PubMed searchClinicalTrials.gov

Other diseases

Familial adenomatous polyposis

家族性腺瘤性息肉病

Led 2 of the 59 English-language PubMed papers on familial adenomatous polyposis with an author in mainland China, 2021–2025: 3.4%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 1120242025: 002025

6 hospitals in Guangzhou for familial adenomatous polyposis76 hospitals in China for familial adenomatous polyposis

No open trial on familial adenomatous polyposis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRadiology / nuclear medicine

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

南方医科大学南方医院

Nanfang Hospital

广州

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR Wikidata
Nanfang Hospital of Southern Medical University; Southern Medical University Nanfang Hospital; Nanfang Hospital Affiliated to Southern Medical University; NanFang Hospital; Nanfang Hospital (L. Li; Departmen of General Surgery Nanfang Hospital; Nanfang Hospital and Basic Medical College; Ganzhou Hospital-Nanfang Hospital

Suggest a correctionDownload the data